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ZUSAMMENFASSUNG 
Protein-Protein Interaktionen (PPI) kontrollieren die Mehrzahl biologischer Funktionen und 
sind in normalen als auch in krankhaften Abläufen die Haupttreiber zellulärer Prozesse. Ein 
solches Maß an Kontrolle wird nur durch einen hohen Grad an Komplexität ermöglicht: z. B 
durch eine große Zahl von PPIs, deren Umkehrbarkeit als auch eine Vielfalt an physikalischen 
und strukturellen Eigenschaften. Darüber hinaus können Bindungs-Affinitäten einen mikro-
molaren bis hohen pico-molaren Bereich umfassen, und manche Proteine agieren als 
Knotenpunkte („hubs“), indem sie mehrere Partner haben. Diese hochentwickelte Organisation 
und Regulierung der PPI erklärt, weshalb Ihre Erforschung so herausfordernd ist. Kein 
einzelner Ansatz kann das gesamte Bild erfassen, und es gibt einen dringenden Bedarf an 
innovativen Plattformen, um die PPI zu studieren und zu analysieren. 
Im Rahmen dieser Doktorarbeit wurde eine neue Plattform, die „Immuno-Competitive Capture 
Mass Spectrometry“ (ICC-MS) konzipiert, um auf unvoreingenommene Weise intrazelluläre 
PPI zu finden. ICC-MS wurde entwickelt, um im Vergleich zur klassischen Affinitäts-
Aufreinigung mit Massenspektrometrie eine höhere Spezifität zu erreichen. Dazu wurde vor 
der Immunopräzipitation ein weiterer Schritt, eine Verdrängung zwischen dem freien und dem 
bindenden Antikörper, eingeführt. Dieser auf Antikörper basierter, auf Isotopen verzichtende 
quantitative Ansatz wurde kombiniert mit einer rigorosen statistischen Analyse, um das 
zelluläre Geflecht der Wechselwirkung von Proteinen besonderen Interesses zu extrahieren und 
zu beleuchten, während unspezifisch bindende Protein herausgefiltert werden. 
ICC-MS wurde zunächst angewendet, um das Interaktom des Hepatitis C viralen, nicht-
strukturellen Protein 5A in humanen Hepatom-Zellen zu beleuchten. Dabei wurde die LATS 
Kinase als möglicherweise wichtiger Regulator der viralen Infektion aufgedeckt. Die 
Untersuchung der Wechselwirkungs-Partner Glypican-2 und HtrA1 hat die Fähigkeit der ICC-
MS bestätigt, eine begrenzte Anzahl von sehr zuverlässigen Interaktionspartnern zu liefern, die 
vielversprechende Kandidaten für eine funktionale Validierung sind. 
Interessanterweise kann ICC-MS auch angepasst werden, um die Interaktionen zwischen 
Proteinen und Oligonukleotiden (Oligo-Competitive Capture Mass Spectrometry, oder OCC-
MS) zu untersuchen. Während es zu einem besseren Verständnis der Wirkungsweise eines 
SMN2 Spleiss-Modifikators beitrug, konnte die Methode jedoch nicht die Rolle von PPI in der 
Toxizität des Antisense-Oligonukleotides aufklären. 
Insgesamt betrachtet ist dieser neue Ansatz geeignet, um den Umfang und die Richtigkeit von 
gegenwärtigen PPI Datenbanken im Sinne einer zutreffenden Darstellung des biologischen 
Interaktoms zu verbessern.  
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ABSTRACT 
 
Protein-protein interactions (PPIs) are controlling the majority of biological functions and are 
the main driver of cellular processes observed in normal as well as pathological conditions. 
Such a level of controlling is only possible via a high degree of complexity; i.e. a massive 
number of protein-protein interactions (in the range of couple hundreds of thousands), a variety 
of physical and structural properties and their reversibility. Moreover, binding affinities can 
span from micro-molar to high pico-molar level and some proteins are acting as “hubs” by 
having multiple partners. This sophisticated organization and regulation of PPIs explains why 
their study is so challenging. No single approaches can capture the full picture and there is an 
urgent need for innovative platforms to study and analyze PPIs. 
In this thesis, a novel platform named Immuno-Competitive Capture Mass Spectrometry (ICC-
MS) was developed to screen in an unbiased fashion intracellular PPIs. ICC-MS was designed 
to reach higher specificity compared to classical affinity purification mass spectrometry by 
introducing a competition step between free and capturing antibody prior to 
immunoprecipitation. This antibody-based label-free quantitative approach was then combined 
with a rigorous statistical analysis to extract the cellular interactome of proteins of interest 
while filtering out non-specifically binding proteins. 
ICC-MS was first applied to elucidate hepatitis C viral non-structural protein 5A interactome 
in human hepatoma cells revealing LATS kinases as potential important regulators of viral 
infection. The study of Glypican-2 and HtrA1 interacting partners further confirmed the ability 
of ICC-MS to deliver a limited number of highly confident interacting proteins being promising 
candidates for functional validation. 
Interestingly, ICC-MS can also be adapted to study interactions formed between proteins and 
oligonucleotides (Oligo-Competitive Capture Mass Spectrometry or OCC-MS). While it 
contributed to a better understanding of the mode of action of an SMN2 splicing modifier, the 
approach could not elucidate the role of protein interactions in antisense oligonucleotides 
toxicity. 
Taken together, this innovative approach is suitable to improve the comprehensiveness and 
accuracy of current protein-protein interactions databases in term of true biological interactome 
representation.  
3 
 
1. INTRODUCTION 
1.1. Protein-protein interactions (PPIs) 
1.1.1 Definition and main characteristics 
A protein-protein interaction (PPI) is defined as a physical contact between two or more 
proteins that is specific and not happening by chance or accident [1]. PPIs are controlling the 
majority of cellular processes and signaling within and outside cells (i.e. metabolism, transport, 
signal transduction, cell-cycle-control, etc.). PPIs drive biological functions both in normal as 
well as in pathological conditions such as cancer, viral/bacterial infections, auto-immune 
disorders or neurodegenerative diseases [2]. 
Such molecular docking is usually emerging for a specific purpose and can be distinguished 
from generic interactions such as those that proteins experienced during their synthesis, folding 
or degradation (i.e. with ribosomal proteins, chaperones or proteins from degradation 
machinery). Those generic interactions are often stable and formed by so-called protein 
subunits (e.g. the spliceosome, the ribosome or nuclear pores). Nevertheless, the majority of 
protein-protein physical interactions are neither static nor permanent and are not necessarily 
present in all cells [3]. 
Attempts to estimate the size of the human protein interactome are reporting between 130’000 
binary interactions based on empirical data [4] to a network size of 650’000 using statistical 
models [5]. Whatever the exact number is, current databases are far from being complete. Some 
proteins are part of so-called “hubs” in which interaction with multiple partners is occurring 
(usually above four). The study of all biological interactions in a given cell is called the 
interactome. 
Despite such a complexity, a more comprehensive analysis of PPIs remains crucial for a better 
understanding of functional relevance, cellular processes and pathways as well as improve 
understanding of the pathology of diseases. 
1.1.2 Structural types and binding affinities 
PPIs vary by their nature, their function, their structure (diversity in the size and shapes of the 
interfaces), their reversibility, their dynamics of assembly and their binding affinities (from 
micro-molar to high pico-molar levels) [6, 7]. 
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The lower level of complexity are protein oligomers, which result from proteins consisting of 
more than one polypeptide chain. Such oligomers can be arranged by multiple copies of the 
same polypeptide (homo-oligomers) or different polypeptides (hetero-oligomers). An example 
of high level of complexity would be the mega-complexes involved in RNA splicing 
(spliceosomes), transcription or translation (ribosomes) and which consist of couple hundreds 
of proteins interconnected. 
One major distinction among PPI is based on whether interactions are permanent or transient 
as well as the range of their associated affinity (from micro-molar to high pico-molar levels) 
and temporal stability (Figure 1.1). 
 
 
Figure 1.1: Protein-protein interactions vary in their affinity. Protein-protein interactions can be 
classified between permanent (with the typical example of the streptavidin-biotin biological interaction, 
the strongest non-covalent interaction known with a dissociation constant, Kd, in the femto-molar 
range) and transient interactions. Transient complexes can be either weak (Kd in the micro-molar range, 
with the example of receptor ligand interactions) or strong (Kd in the nano-molar range) which are 
associated with a greater temporal stability. The Kd is inversely correlated to the binding affinity. 
Covalent binding is the highest affinity association between two proteins (via disulfide bonds 
or sharing of electrons) and is rarely the case of PPIs with the exception of SUMO proteins or 
ubiquitin. Transient and reversible PPIs are dynamic and cover most interactions involved in 
biochemical cascade [8]. Those interactions are mediated via hydrogen bonds, hydrophobic 
interactions, ionic interactions or van der Waals interactions, which are weak but can be 
distributed across multiple sites between the interacting proteins leading to a cumulative 
affinity. 
PPIs can be mediated via PPI domains (peptide recognition motifs) but also outside specific 
amino-acid sequence or even in unfolded regions. Multiple PPI domains exist which are 
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evolutionary conserved among specific protein families with the most well-defined being the 
Src homology (SH1, SH2, SH3), Phosphotyrosine-binding (PTB), Pleckstrin homology (PH) 
and PDZ domains involved in cellular signal transduction [9]. 
1.1.3 Cellular regulation 
PPIs are regulated to occur at a given time point and in a given location [10]. This spatial and 
temporal events are controlled at multiple levels via local protein concentration, protein 
affinity, presence of other proteins, co-localization of partners and physicochemical 
environment (pH, temperature, ions concentration). Allosteric regulation via small ligand 
binding (outside of the active site, discussed in paragraph 1.2.2.) or post-translational 
modification (PTM, such as phosphorylation, acetylation or hydroxylation) [11] will either 
change the amino-acid chemical properties involved in binding or affect protein folding. In 
addition to allosteric regulation, phosphorylation can create docking sites to interact with other 
proteins (e.g. SH2 and PTB recognizing phosphorylated tyrosine). 
As cellular microenvironment has such an impact on protein interactions, it is critical to study 
PPIs as much as possible in in vivo-like conditions to ensure for their biological relevance. 
 
1.2 Disease directly associated with PPIs 
1.2.1 Pathologies 
Unwanted aberrant or dysregulated PPIs are the cause of many and diverse pathologies [12]. 
Biochemical dysfunction is often caused by mutations in a binding domain or leading to protein 
allosteric changes. In the case of bacterial or viral infections, host-pathogen interactions are 
also playing a key role. Table 1.1. is listing a few pathologies having a direct link to PPIs. 
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Abnormal PPIs Example of 
pathology 
Molecular observations 
Protein-DNA 
disruptions 
Cancer Mutation on p53’s DNA binding domain preventing 
transcriptional activation of anti-cancer mechanisms 
Protein misfolding Von Hippel-Lindau 
syndrome 
Y98H mutation in VHL binding site preventing 
interaction with HIF 
Host-pathogen 
interactions 
HPV-induced 
carcinogenesis 
E6 and E7 viral proteins bypassing immune system 
via interaction with host regulators 
New undesired 
protein interactions 
Huntington’s 
disease 
Polyglutamine sequence elongation leading to 
huntingtin aggregation 
Table 1.1: PPIs in human diseases. Aberrant PPIs are causing diverse pathologies. 
1.2.2 PPIs as therapeutic targets 
Due to their central role in biological processes and their links to pathologies, targeting the 
interfaces between interacting proteins both extracellularly and intracellularly represent 
promising therapeutic approaches [13, 14]. In the past, PPIs were defined as extremely 
challenging to target and intractable. Nevertheless, advancing our understanding of PPIs in the 
past decades enabled the development of potent PPI inhibitors targeting more than 40 PPIs 
with some of them having reached clinical trials (e.g. the anticancer drug idasanutlin occupying 
p53 binding pocket of MDM2). Notably, the contact surfaces are much larger (around 1’500 
up to 3’000 Å) compared to those usually found between proteins and small-molecules (around 
300 up to 1’000 Å). The nature of the surface is also drastically different. In protein-protein 
interactions contact surfaces are generally flat in contrast to deep grooves or pockets often 
bound by small molecules on proteins. Mutational studies revealed that not all residues from 
the contact surfaces are critical but that binding is occurring via so called “hot spots” which 
tend to be clustered at the center of the contact surface covering an area of the size of a small 
molecule. 
Identification of small molecule has been strongly advanced by methods such as fragment-
based lead discovery using biophysical methods (crystallography, surface plasmon resonance, 
nuclear magnetic resonance). Their binding affinities can be similar to that of the native protein 
partner. High-affinity small molecules can interact with residues that are not engaged with 
native protein partners or even deep pockets on the protein contact surface. 
Although contact surfaces in PPIs often involve non-contiguous amino-acid residues, some 
inhibitors have been developed targeting primary peptide epitopes (short and continuous 
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peptides). Such inhibitors have been discovered either via fragment-based biochemical or cell-
based screenings. The native ligand is usually close to the size of a small-molecule inhibitor. 
One example being tirofiban, mimicking a linear tripeptide Arg-Gly-Asp, the epitope of 
fibrinogen binding integrin IIbIIIa and thereby preventing the blood from clotting. 
PPI inhibitors have been also developed to target secondary structure epitopes (extended 
binding sites such alpha helix or beta sheets) as well as tertiary structural epitopes (globular 
discontinuous binding sites). In those cases, key peptide residues are not contiguous in the 
primary sequence. A famous example targeting secondary structure epitopes are the Nutlins 
identified by HTS and which are binding MDM2 in the p53-binding pocket activating the p53 
pathway in cancer cells [15]. 
PPIs inhibitors screens can deliver orthosteric inhibitors (binding the active site) but can also 
led by chance to the identification of allosteric mechanism of inhibition either inhibiting 
binding via altered conformation or even promoting aberrant interactions. 
PPIs inhibitors are interesting molecules to treat viral infection as viruses hijack host proteins 
to facilitate their entry and replication. An example of a drug on the market is Maraviroc, an 
anti-HIV drug used as part of combination therapy and which inhibit virus entry by interacting 
with CCR5 found on the surface of cells of the immune system. 
In this context, a better understanding of PPIs would definitely help to design PPIs inhibitors 
and would ultimately increase their prevalence into HTS libraries, which are currently biased 
as derived mostly from historical medicinal chemistry efforts in pharmaceutical companies. 
 
1.3 Mapping the protein-protein interaction network 
A cell can be considered as a web of complex interactions between macromolecules. Those 
complex systems are usually simplified by nodes (proteins) and edges (physical interactions). 
Edges usually do not have a direction as it is not always known which protein is functionally 
influencing the other [16] (the same for the distinction of activation versus repression). 
Interactome networks can be generated via different strategies. One strategy consists on 
compiling and curating existing and publicly available data. The accuracy of such maps is 
dependent on the methods used, which should be ideally standardized and unbiased. When 
combining multiple small-scale experiments, it is not possible to control for accuracy, 
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sensitivity and reproducibility. Another option is the use of unbiased high-throughput 
experimental strategies, which largely contributed in the last decade to the improvement of 
databases coverage [17]. On top of those empirical methods, computational techniques can be 
employed to predict interactions. Those predictions are usually based on factors such as amino-
acid composition, structural information, phylogeny, gene conservation, domain co-
occurrence, sequence similarities, post-translation modifications and sub-cellular location [30, 
31]. Such computational methods differ from physical or biochemical approaches by using 
rather indirect information. To generate accurate map of PPIs, both completeness (number of 
pairs tested) and precision (proportion of true interactors) have to be taken into consideration. 
 
1.4 Experimental strategies to profile PPIs 
1.4.1 Co-complex and binary methods 
In the past, biophysical methods were applied to study individual PPIs, mainly based on 
structural information (e.g. X-ray or NMR) [18]. More recent approaches to study PPIs are 
divided between those measuring direct physical interactions between protein pairs (binary 
methods) and those measuring physical interactions among group of proteins (co-complex 
methods) [1, 3]. Each method has its own strengths and weaknesses and usually a combination 
of approaches is needed to elucidate PPIs with sufficient confidence. Table 1.2 is summarizing 
the most popular approaches with their respective assets as well as limitations. 
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Table 1.2: List of most popular approaches to screen PPIs. Approaches can be divided between 
binary and co-complex approaches and each has its own advantages and limitations. AP-MS: Affinity 
purification coupled to mass spectrometry, Y2H: Yeast two-hybrid, SPR: Surface plasmon resonance 
and FRET: Fluorescence resonance energy transfer. 
Among system-wide mapping methodologies, the most popular are the yeast two-hybrid 
system (Y2H) and the affinity purification coupled to mass spectrometry (AP-MS). 
1.4.2 Yeast two-hybrid (Y2H): a system-wide binary method 
The Y2H technique was first described in 1989 [19] and is testing the interaction between two 
proteins (bait and prey) via fusion to a transcription-binding domain within a yeast system. 
Upon interaction, the complex is activated and reporter gene are transcribed leading to 
detection of its product. Its main advantage is its adaptation to high-throughput screening 
(HTS). Y2H was the first approach able to interrogate the protein interactome on a genome 
scale [4, 20, 21]. On the other side, by forcing two proteins to localize to the nucleus, misfolding 
and aggregation of membrane proteins can occur which can explain lower detection rate as 
well as a bias toward non-specific interactions. In addition, mammalian proteins expressed in 
yeast are not necessarily harboring the PTMs usually relevant for their function and which may 
guide specific interactions. 
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1.4.3 Affinity purification coupled to mass spectrometry (AP-MS): a system-wide 
co-complex method 
Co-complex methods are capturing both direct and indirect associations within a complex. 
Subsequently, additional technologies are needed to distinguish direct versus indirect 
interactors. The most popular technology is the combination of affinity purification and mass 
spectrometry (AP-MS, Figure 1.2.) where prey proteins are co-captured with an affinity 
captured bait protein. AP-MS appeared more than a decade ago and is combining the sensitivity 
of immunocapture together with the power of MS readout [22-24]. The bait protein is either 
the endogenous protein when a specific and selective antibody is available or a tagged version 
(e.g. with GST, FLAG, HA, 6xHis or Myc) expressed in cells [25, 26] ideally close to in vivo 
concentration. The first option (called label-free) might be favored whenever possible as 
classical tags can lead to protein misfolding and may expose hydrophobic surfaces that result 
in artificial interactions (false positive) [27]. However, it is crucial to select an antibody with a 
good efficiency of affinity depletion and high specificity. Even after rigorous antibody 
selection (e.g. with the help of public database mining [28]), one major drawback of classical 
AP-MS approach remains the lack of specificity. Indeed, the main challenge with AP-MS is to 
discern bona fide interactors from highly abundant cellular proteins or proteins binding 
nonspecifically to the affinity matrix. Strategies to overcome this limitation will be discussed 
in section 1.6. 
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Figure 1.2: Overview of affinity purification coupled to mass spectrometry (AP-MS) workflow. A 
protein of interest (or the bait, in orange) is affinity purified from a cell lysate together with its direct 
interacting partners (or preys, in dark blue and dark green), indirect partners (in light blue and light 
green) as well as contaminants (in grey, typically highly abundant proteins or sticky by nature). Proteins 
are then digested into peptides (usually with trypsin), which are analyzed by mass spectrometry (MS). 
Not represented are separation of peptides by reversed-phase liquid chromatography and the two MS 
events. In a first scan, mass/charge ratio (m/z) of intact peptides is measured. A second scan is then 
applied on the most abundant peptides, which are fragmented into smaller fragment ions (e.g. by 
collision-induced dissociation or CID) generating a tandem MS (MS/MS) spectrum. Database searching 
is then matching spectra with in-silico predicted peptides (mass & sequence) generating a list of proteins 
present in the sample (including the bait, co-complexes and contaminants). 
Above mentioned methodologies can be done in a low-throughput fashion (interactome of a 
single protein of interest) or in a high-throughput format to map global interactomes. Quite 
recently, four human interactome maps have been published which led to the identification of 
almost 93’000 unique proteins interactions and associations (indirect interactions detected by 
co-complex method) (reviewed in [29]). Their overlap is low which is rather explained by the 
fact that each map has been generated using different methodologies/protocols than by 
potential concerns in data quality. Only a combination of approaches can capture the different 
features of the human interactome. 
 
1.5 Protein-protein interactions databases 
PPIs databases are combining the knowledge arising from empirical as well as computational 
methods together with text mining [30]. An example of a popular database storing interaction 
data is BioGRID (https://thebiogrid.org/) which is currently covering more than 30’000 unique 
human PPIs. BioGRID together with DIP (https://dip.doe-mbi.ucla.edu) or IntAct 
(https://www.ebi.ac.uk/intact/) are primary databases collecting information about 
experimentally proven PPIs via small or large-scale experimental methods. As each database 
is lacking a proportion of total PPIs, it is crucial to integrate information to increase coverage 
[3]. Meta-databases are integrating information from different primary databases for example 
APID (http://apid.dep.usal.es) and PINA (https://omictools.com/pina-tool). Confidence of 
interactions will be based on the number of experimental proofs reported. STRING 
(http://string-db.org) is another example of such web-based interface combining genomic 
context, experimental evidences, co-expression and text mining. Depending on the level of 
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confidence score set, it can lead to many false positives. It is then possible to combine PPIs 
information with additional parameters such as gene expression, genetic interaction, 
colocalization or Reactome/KEGG signaling/metabolic pathways. Combining such 
heterogeneous data is challenging but provide additional confidence that an interaction might 
be leading to a biological effect. One of the most widely used open source bioinformatics tool 
modeling networks is Cytoscape (www.cytoscape.org).  
At the end, the extent to which databases are reflecting the biologically relevant interactome 
remains unknown. Current knowledge of the interactome is still incomplete and noisy. This 
can be explained by the limitations of the methods to detect truly physiological interactions 
associated with the identification of many false positives and false negatives. Current databases 
are biased towards highly expressed proteins and well-studied pathways. To increase 
reliability, non-reported true negative proteins should be incorporated (i.e. when an interaction 
has been studied and result was negative). There is currently no effort to refine the network by 
eliminating false positive. Despite extensive efforts, the human interactome is still a work in 
progress. 
 
1.6. Strategies to increase AP-MS specificity and improve databases’ 
accuracy 
As previously mentioned, AP-MS is a powerful and widely used approach to profile in an 
unbiased manner interacting partners of endogenous proteins and by such is largely 
contributing to interactome databases. AP-MS is applied for the analysis of protein complexes 
and interactions networks either of small-scale (targeted interactome of one protein of interest), 
medium-scale (interactome of protein members of a family) or large-scale (systematic tagging 
of open reading frames, ORFs [31, 32]). In any cases, filtering out background contaminants 
co-purified with bait proteins and subsequently identified by MS is challenging but crucial in 
order to improve accuracy of those databases. The majority of contaminants are proteins 
binding non-specifically to the affinity matrices (e.g. sepharose, agarose or magnetic beads). 
There is also a clear relationship between the abundance of a protein and its detection as 
contaminants. At the end, the percentage of true interaction partners usually represent less than 
10% of all identified proteins [33]. 
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1.6.1. Computational approaches 
Various scoring methods have been developed to rank interaction partner specificity [34]. 
Earliest methods for filtering AP-MS datasets were based on binary comparison (presence or 
absence of a protein). Quantitative information was then incorporated such as spectral counts 
or peak intensity in label-free quantification. Including multiple replicates in an experimental 
design is allowing more rigorous statistics such as t-test where p-values indicate whether an 
observed fold change in abundance is statistically significant based on the variance across all 
replicates. Combining then p-values with the magnitude of fold change (for example in a 
Volcano plot) finally improve the distinction between false and true interactors. The latter is 
likely to have a high fold change and high significance (low p-value). 
It is also possible to screen a dataset against a set of negative controls formerly generated by 
the proteomics research community (published and unpublished) for example using the 
CRAPome web-accessible resource (https://www.crapome.org/) [35]. It implies that raw mass 
spectrometry files are processed via a uniform data analysis pipeline. To score interactions, 
both the abundance levels of co-precipitating proteins and their occurrence in negative controls 
are taken into account. The type of background identified is clearly linked to the experimental 
conditions, that is why it is recommended whenever possible to keep some user controls in 
addition to the controls deposited in CRAPome. For large-scale studies in absence of negative 
controls, alternative scoring models exist which are based on the analysis of a prey compared 
to its purification with different baits (SAINT [36], ComPASS [37], MiST [26]). A true 
interactor in these models are proteins having a high intensity (abundance) over replicated 
experiments (reproducibility) but only with a few baits (specificity). 
With any of the above-mentioned tools, proteins classified as “non-specific” should be tagged 
rather than excluded. Indeed, a highly abundant protein (such as keratin, cytoskeletal proteins, 
histones, ribonucleoproteins or heat-shock proteins) or a promiscuous protein can be a true 
interactor to a specific protein in particular conditions. Computational efforts to refine data 
analysis need to be combined with experimental strategies that improve the selectivity at the 
IP step. 
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1.6.2. Experimental strategies 
There is a great need for novel experimental strategies aiming at reducing the rate of false 
positives in AP-MS experiments. It is possible to increase the stringency of purification 
methods (e.g. by increasing the number of washes or salts concentration) but although this 
would result in a reduction in the level of nonspecific binding, it would also potentially remove 
specific binders of low affinity or low abundance. A pre-clearing step on the matrix might also 
lead to a loss of information. 
The best strategy to filter out contaminants to date is to combine the use of negative controls 
with quantitative proteomics [33, 38]. A control experiment is performed in parallel of AP of 
the protein of interest and abundance ratios are then quantitatively compared [38]. The three 
most common labeling techniques used in AP-MS experiments are ICAT (chemical labeling at 
level of protein), iTRAQ (chemical labeling at level of peptide) and SILAC (metabolic labeling 
at level of organism/cell) [39]. 
A mock purification using the support resin only or using a control antibody even of the same 
isotype are considered as poor controls. An example of a suitable negative control is a cell line 
that does not express the bait proteins (e.g. by knock-down or parental cell line versus the one 
expressing tagged protein). As minor variations in sample or sample preparation can greatly 
influence the capture of proteins, the closer the control is to the actual experiment, the better. 
Silencing approaches can be quite efficient when incorporated in the workflow to identify 
target related binders but is quite labor intensive [40]. Replicates are also needed to increase 
confidence of AP-MS experiments, at least triplicates to allow for statistics. Nevertheless, 
classical quantitative side-by-side comparison of a sample with its control still suffers from the 
fact that the control sample is not identical to the probed one and both samples can lead to the 
association of different nonspecific binders. 
In this thesis an innovative way to filter out non-specific binders is proposed leading to an 
approach combining specificity, simplicity and proteome wide accessibility. 
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1.7. Aims and objectives 
 
Protein-protein interactions (PPIs) are controlling the majority of biological processes. PPIs 
are diverse and organized in complex networks, which explains why their study is so 
challenging. None approaches can capture the full complexity and there is a big need for 
innovative platforms to ultimately improve reliability of current protein-protein databases. 
The most popular platform is the combination of affinity purification and mass spectrometry 
(AP-MS) although with such an approach it is challenging to distinguish true interactors from 
non-specific binders.  
The aim of this work was to overcome the limitation of classical AP-MS approaches in term 
of specificity by decreasing the number of false-positives. The Immuno-Competitive Capture 
Mass Spectrometry platform (ICC-MS) is a three steps approach combining a competitive 
binding (pre-competition step using the free form of the same antibody as the capture antibody) 
prior to subsequent affinity purification and mass spectrometry analysis. A statistical analysis 
is then applied on MS signals to extract the cellular interactome of proteins of interest while 
filtering out background proteins. 
Within this dissertation, the first task was to run a proof-of-concept in a viral-host model (HCV 
NS5A in Con1-Huh-7). Next, the capability of ICC-MS to deliver a limited number of 
interacting candidates with highest potential for biological relevance was further assessed. For 
this purpose, Gpc2 and Htra1 cellular interactome were executed respectively in a human 
neural stem cell model and in a retinal pigmented epithelial model. 
The last task was to adapt the protocol to the screening of oligonucleotide-protein interactions. 
Oligo-Competitive Capture Mass Spectrometry (OCC-MS) was evaluated in the context of 
RNA-protein and single-stranded antisense oligonucleotide-protein interactions. 
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2. MATERIAL & METHODS 
2.1. Material 
2.1.1 Chemicals and solutions 
Chemical / solution Manufacturer 
Accutase Sigma-Aldrich 
Acetic acid Sigma-Aldrich 
Acetonitrile Biosolve 
Ammonium Bicarbonate Fluka 
ATP SignalChem 
BCA Protein Assay kit Thermo Scientific 
Bradford Assay Reagent Thermo Scientific 
CaCl2 Merck 
Colloidal Blue Staining Kit Invitrogen 
Dithiothreitol Roche Applied Sciences 
Dulbecco's Modified Eagle Medium (D-MEM), high glucose Gibco 
D-MEM, high glucose, GlutaMAX, Pyruvate Gibco 
Ethanol  Merck 
Ethanolamine Aldrich Chemistry 
FBS Sigma 
FBS heat inactivated Sigma 
Formic acid Fischer Chemicals 
Geneticin Gibco 
Hepes Gibco 
Iodoacetamide Sigma-Aldrich 
KCl Sigma-Aldrich 
Kinase activity buffer SignalChem 
Lumi-Light Western Blotting Substrate Roche Applied Sciences 
MagicMark XP Western Protein Standard Thermo Fischer Scientific 
Mark12 unstained standard Invitrogen 
Methanol Sigma 
MgCl2 Merck 
Milk powder Fluka 
NaCl Merck 
Nonidet P-40 Calbiochem 
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Nupage Sample Reducing agent Life Technologies 
Phosphate buffered saline Gibco 
Penicillin-Streptomycin Gibco 
Phosphatase Inhibitor Cocktail PhosSTOP Roche Applied Sciences 
Pro-Q Diamond Phosphoprotein Gel Stain Thermo Fischer Scientific 
Protease inhibitor Cocktail Complete EDTA free Roche Applied Sciences 
Protector RNase inhibitor Roche Applied Sciences 
SeeBlue Plus 2 pre-stained protein standard Invitrogen 
Sodium azide Sigma 
SuperSignal West Femto Pierce 
Sypro Ruby Protein Gel Stain Thermo Fischer Scientific 
Tris base Applichem 
Tris-Glycine SDS Running Buffer Invitrogen 
TrypLE Express (cell collection) Gibco 
Trypsin (cell collection) Gibco 
Trypsin (protein digestion) Promega 
Tween 20 Sigma-Aldrich 
2.1.2 Devices 
Devices Manufacturer 
Automated cell counter Bio-Rad 
Blotter Bio-Rad 
Cell culture microscope Primovert Zeiss 
Cell incubator Thermo Scientific 
Concentrator Eppendorf 
Criterion tank Bio-Rad 
Laminar flow Skan, Telstar 
LTQ-Orbitrap Velos Thermo Scientific 
Luminescent image analyzer LAS4000 Fujifilm 
Magnetic stirrer IKA 
Micromix5 DPC 
Microplate reader Molecular Devices 
MilliQ ultrapure water system Millipore 
Mutlichannel pipette Rainin  
Multi-rotator Grant Bio 
MixMate Eppendorf 
Nanodrop spectrophotometer Thermo Scientific 
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Nanoflow Easy-nLC Thermo Scientific 
Orbital shaker IKA 
pH meter Mettler Toledo 
Pipetboy Integra 
Pipettes (10, 20, 100, 200, 1000, 2500 µl) Eppendorf 
Power supply PowerPac Bio-Rad 
Thermomixer Eppendorf 
Thermo Sealer Thermo Scientific 
Q125 Sonicator Qsonica 
Tribrid Orbitrap Fusion Thermo Scientific 
Tubes and plates centrifuge Eppendorf 
Vortex Scientific Industries 
Weighing scale Mettler Toledo 
XCell Sure Lock Invitrogen 
2.1.3 Consumables 
Consumables Manufacturer 
Acclaim PepMap Thermo Scientific 
Affi-Gel 10 beads Bio-Rad 
Aluminum foil lids Beckman Coulter 
AQUA C18 Trap Phenomenex 
BC2-Nanotrap (Rothbauer, 2016) 
Cell Culture Flasks T-25, T-75, T-125 Corning 
Cell scraper Sarstedt 
Combitips (0.5, 2.5, 5, 10 mL) Eppendorf 
Easy spray column PepMap C18 Thermo Scientific 
Falcon pipettes (2, 5, 10, 25 mL) Corning 
Falcon tube (15, 50mL) Corning 
GFP-Trap ChromoTek 
LoBind tubes (0.5, 1, 1.5, 2, 5 mL) Eppendorf 
Novex Tris-Glycine SDS sample buffer Life Technologies 
Novex 4-20% Tris-Glycine Invitrogen 
Petri dish Corning 
pH indicator strips Macherey-Nagel 
Pipette tips (10, 20, 200, 1000, 2500 µL) Rainin, Eppendorf 
PVDF membrane Millipore 
Reprosil-Pur C18-AQ Dr. Maisch 
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REMP Sealing and piercing fil Brooks Life Sciences 
SteriCup Merck 
Surgical disposable scalpel Braun 
Syringe Hamilton 
Tip-Tub reservoir Eppendorf 
TopSeal Perkin Elmer 
Zeba Spin desalting column Pierce 
4-20% CriterionTMTGXTM Precast gel Bio-Rad 
96 well flat-bottom Thermo Scientific 
96 well filter plate Millipore 
96 well PCR plate Thermo Scientific 
96 well perforated plate Proxeon 
96 well V-bottom Greiner Bio-one 
2.1.4 Antibodies 
Following primary and secondary antibodies were used in this study 
2.1.4.1 Primary antibodies 
Antibody (species) Manufacturer 
Anti-Aconitase (rabbit, pAb) Abcam 
Anti-C1QTNF5 (mouse, mAb) R&D Systems 
Anti-C1QTNF5 (pig, pAb) LSBio 
Anti-C1QTNF5 (rabbit, pAb) Sigma-Aldrich 
Anti-FGF2 (rabbit, pAb) Abcam 
Anti-hnRNP A1 (ROA1) (rabbit, pAb) Abcam 
Anti-HTRA1/PRSS11 (mouse, mAb)  R&D Systems 
Anti-HTRA1 (in house) (Vierkotten, 2011) 
Anti-HuR (mouse, mAb) Thermo Scientific 
Anti-H2B (rabbit, pAb) Merck 
Anti-LaminB (rabbit, mAb) Abcam 
Anti-LATS1 (rabbit, pAb) Abcam 
Anti-LATS1 C66B5 (rabbit, mAb) Cell Signaling Technology 
Anti-LATS2 (rabbit, pAb) Abcam 
Anti-LATS2 D83D6 (rabbit, mAb) Cell Signaling Technology 
Anti-NS5A 7D4 (mouse, mAb) Santa Cruz Biotechnology 
Anti-NS5A H26 (mouse, mAb)  Abcam 
Anti-NS5A H110B (mouse, mAb) Thermo Scientific 
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Anti-Tubulin beta KMX-1 Sigma-Aldrich 
Anti-Tubulin beta III Abcam 
Anti-14-3-3 alpha beta (rabbit, pAb) Abcam 
2.1.4.2 Secondary antibodies 
Antibody (species) Manufacturer 
Anti-mouse (goat) IgG Jackson Laboratories 
Anti-rabbit (goat) IgG Jackson Laboratories 
2.1.4.3 Recombinant proteins 
Recombinant protein Manufacturer 
Human LATS2 kinase SignalChem 
NS5AΔ32 BK strain Roche Nutley 
Human Glypican 2 R&D Systems 
FGF2 PeproTech 
2.1.5 Oligonucleotides 
2.1.5.1 Antisense oligonucleotides (ASOs) 
Antisense oligonucleotide Target Sequence 5' to 3' 
ASO-A VEGF TmCTcctcttccttmCAT 
Bio-ASO-A VEGF 5’-BioHEG-TmCTcctcttccttmCAT 
ASO-B PCSK9 TGmCtacaaaacmCmCA 
GalNac ASO-B PCSK9 5’-GN-C6caTGmCtacaaaacmCmCA 
Bio-ASO-B PCSK9 TGmCtacaaaacmCmCA-BioTEG-3’ 
GalNac Bio-ASO-B PCSK9 5’-GN-C6caTGmCtacaaaacmCmCA-BioTEG-3’ 
ASO-C PCSK9 GmCtgtgtgagcttGG 
GalNac ASO-C PCSK9 5’-GN-C6GmCtgtgtgagcttGG 
Bio-ASO-C PCSK9 GmCtgtgtgagcttGG-BioTEG-3’ 
GalNac Bio-ASO-C PCSK9 5’-GN-C6GmCtgtgtgagcttGG-BioTEG-3’ 
ASO-D Myd88 CACattccttgctCTG 
MOD ASO-D Myd88 CACattccttgctCTG 
Bio-ASO-D Myd88 BioTEG-CACattccttgctCTG 
Table 2.1: List of ASOs with their respective targets and 5’ to 3’sequence 
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Antisense oligonucleotide Provider 
ASO-A Erich Koller, Roche Innovation Center Basel 
Bio-ASO-A Susanne Kammler, Roche Innovation Center Copenhagen 
ASO-B Sabine Sewing, Roche Innovation Center Basel 
GalNac ASO-B Sabine Sewing, Roche Innovation Center Basel 
Bio-ASO-B Adrian Schäublin, Roche Innovation Center Basel 
GalNac Bio-ASO-B Adrian Schäublin, Roche Innovation Center Basel 
ASO-C Sabine Sewing, Roche Innovation Center Basel 
GalNac ASO-C Sabine Sewing, Roche Innovation Center Basel 
Bio-ASO-C Adrian Schäublin, Roche Innovation Center Basel 
GalNac Bio-ASO-C Adrian Schäublin, Roche Innovation Center Basel 
ASO-D Microsynth 
MOD ASO-D Microsynth 
Bio-ASO-D Microsynth 
Table 2.2: List of ASOs with their respective providers 
2.1.5.2 Oligonucleotides 
Oligonucleotide mRNA Sequence 5' to 3' 
ESE2 SMN2 exon 7 AAAAAGAAGGAAGG  
Bio-ESE2 SMN2 exon 7 AAAAAGAAGGAAGG-Bio 
AR 
Androgen 
Receptor 3' UTR 
CUGGGCUUUUUUUUUCUCUUUCUCUCCUUUCUUUU
UCUUCUUCCCUCCCUA 
Bio-AR 
Androgen 
Receptor 3' UTR 
CUGGGCUUUUUUUUUCUCUUUCUCUCCUUUCUUUU
UCUUCUUCCCUCCCUA-Bio 
IRE 
UTR of various 
mRNAs (e.g. 
ferritin) UCCUGCUUCAACAGUGCUUGGACGGAAC 
Bio-IRE 
UTR of various 
mRNAs (e.g. 
ferritin) UCCUGCUUCAACAGUGCUUGGACGGAAC-Bio 
Table 2.3: List of oligonucleotides with their respective mRNA and 5’ to 3’sequence 
Oligonucleotide Provider 
ESE2 Manaswini Sivaramakrishnan, Roche Innovation Center Basel 
Bio-ESE2 Manaswini Sivaramakrishnan, Roche Innovation Center Basel 
AR Pierce™ Magnetic RNA-Protein Pull-Down Kit 
Bio-AR Sonja Meier, Roche Innovation Center Basel 
IRE Sonja Meier, Roche Innovation Center Basel 
Bio-IRE Pierce™ RNA 3' End Biotinylation Kit 
Table 2.4: List of oligonucleotides with their respective providers 
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2.2. Methods 
2.2.1 Cell culture methods 
2.2.1.1 Huh7 parental cell line and human hepatocyte-derived Con1-Huh7 cells (Con1-
Huh7) 
Huh7 cells and Huh7 cells stably expressing Con-1 genotype 1b and the renilla luciferase 
reporter gene (Huh7 2209–23) [41] were provided by Junjun Gao (former Hoffmann-La Roche 
site in Nutley) as previously described [42]. Cells were cultured/maintained in DMEM high 
glucose supplemented with GlutaMAX, sodium pyruvate (110 mg/l), heat inactivated FBS and 
antibiotics (500 μg/ml penicillin-streptomycin, 500 μg/ml geneticin) at 37°C in a humidified 
chamber with a 5% CO2 atmosphere. Cells were detached using 0.05% trypsin-EDTA (5 min 
at 37°C under 5% CO2) and harvested by centrifugation (3 min at 150 x g). 
2.2.1.2 Differentiated human neural progenitor (d21 NSC) and human Gpc2 transfected H4 
neuroglioma cells (hGPC2 H4) 
Differentiated neural progenitor cell pellets and human Gpc2 transfected H4 neuroglioma cell 
pellets were provided by Sebastian Kim Lugert (Roche Innovation Center Basel) [43]. 
2.2.1.3 Human fetal retinal pigment epithelial cell (hfRPE) 
Human RPE were provided by the lab of Roberto Iacone (Esther Melo, Corinne Stucki and 
Frédéric Delobel, Roche Innovation Center Basel) [44]. For collection from transwells, cells 
were washed with PBS and incubated with accutase (at 37°C and under 5% CO2 until the cells 
are detached) and scraped off. Finally cells were harvested by centrifugation (3 min at 150 x 
g). 
2.2.1.4 Human SMA type 1 fibroblasts 
SMA type 1 fibroblasts were provided by the lab of Friedrich Metzger (Roche Innovation 
Center Basel) and maintained in DMEM (high glucose) supplemented with GlutaMAX, 110 
mg/l pyruvate and 10% heat inactivated FBS at 37°C under 5% CO2. For collection, cells were 
detached using trypLE Express (1 min at 37°C under 5% C02) and harvested by centrifugation 
(3 min at 150 x g). 
2.2.1.5 Human renal proximal tubular epithelial cell (PTEC) 
PTEC-TERT1 were provided by Laurence Hilfiger from the lab of Marcel Gubler (Roche 
Innovation Center Basel) according to the published protocol [45]. Cells were then maintained 
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in DMEM/F12 supplemented with 2% FBS, detached with 0.05% trypsin-EDTA (5 min at 
37°C under 5% CO2) and harvested by centrifugation (3 min at 150 x g). 
2.2.1.6 Human embryonic kidney 293 cells (Hek293) 
Hek293 cells were maintained in DMEM (high glucose) containing 10% FBS at 37°C under 
5% CO2. For collection, cells were detached using 0.05% trypsin-EDTA (5 min at 37°C under 
5% CO2). 
 
2.2.2 Biochemical methods 
2.2.2.1 Mammalian cell lysis 
Harvested PTEC, Hek293, d21 NSC, hGpc2 H4, hfRPE cells (fresh pellets or stored at -20°C) 
were resuspended in a PBS buffer supplemented with 1% (v/v) Nonidet P-40 and protease 
inhibitor. RNase inhibitor was also added for ASO pull-down experiments. After 15 min on 
ice, lysates were cleared by centrifugation at 4°C (10 min at 20’000 x g). 
Harvested Huh7 and Con1-Huh7 replicon cells were resuspended in a 50 mM Tris pH 7.5 lysis 
buffer containing, 150 mM NaCl, 0.5% (v/v) Nonidet P-40, protease inhibitor and phosphatase 
inhibitor. After 15 min on ice, lysates were cleared by centrifugation at 4°C (10 min at 1’500 
× g). 
To generate SMA type 1 human fibroblasts nuclear extracts, harvested cells were first 
resuspended in Hepes 10mM pH 7.8 supplemented with MgCl2 1mM, KCl 10mM, protease 
inhibitor and homogenized with a potter (8 strokes at 800 rpm). Lysates were centrifuged at 
4°C (10 min at 500 x g). The supernatant was collected (cytosolic fraction) and pellets were 
resuspended in a 50 mM Hepes pH 7.3 buffer containing 150 mM NaCl, 1 mM CaCl2, 1 mM 
MgCl2, 0.5% (v/v) Nonidet P-40, EDTA-free protease inhibitor and RNase inhibitor. After two 
sonication cycles (each 10 pulses of 1 second with 1 second of pausing between each pulse) at 
an amplitude of 60%, samples were finally cleared by centrifugation at 4 °C (10 min at 300 x 
g). 
Protein concentrations were estimated using the bicinchoninic acid protein assay according to 
manufacturer’s protocol (Thermo Fischer Scientific). 
24 
 
2.2.2.2 Tissue extraction 
Mouse livers and kidneys (courtesy of Roche comparative pharmacology department) were 
weighted and 8 ml per gram of tissue of PBS buffer supplemented with 1% (v/v) Nonidet P-40 
and protease inhibitor was added. After 10 min incubation on ice, tissues were extracted 
mechanically using a potter (8 strokes at 800 rpm) followed by two sonication cycles (each 10 
pulses of 1 second with 1 second of pausing between each pulse) at an amplitude of 60%. 
2.2.2.3 SDS-PAGE and Western blot 
Proteins were separated by size on 4-20% Tris-Glycine denaturing polyacrylamide gels. 
Samples containing 1 x Laemmli sample buffer (0.1% 2-Mercaptoethanol, 0.0005% 
Bromophenol Blue, 10% Glycerol, 2% SDS in ddH2O) were denaturated by adding reducing 
agent (DTT, 50mM final) followed by a boiling step at 85°C for 5 min. Separation was done 
either by running the gel fully (with Invitrogen precast gels), or only half its length (with Bio-
Rad precast gels) according to Table 2.5. A short 1 cm migration (with Bio-Rad precast gels) 
was performed to eliminate SDS only. Gels were fixed for 1 hour in a fixation solution (40% 
ethanol, 10% acetic acid). 
Migration Voltage 
Full 60 V for 20 min and 2 hrs at 125 V 
Half 100 V for 10 min and 30 min at 150 V 
1 cm 100 V for 10 min and 5 min at 150 V 
Table 2.5: Voltage and time of migration 
Separated proteins were either stained with Coomassie blue (Colloidal Coomassie blue in a 
methanolic solution supplemented with ammonium sulfate and phosphoric acid) or transferred 
to a PVDF membrane by Western blotting. 
For Coomassie staining, gels were stained either overnight or at least for 3 hours under agitation 
at room temperature. Gels were finally rinsed in water. 
Proteins were transferred from gels to 0.45 µm PVDF membranes at 100 V for 1 hour in a 
transfer buffer (Tris 25 mM, glycine 192 mM, methanol 5%). Membranes were blocked for 1 
hour at room temperature in Tris buffered saline (TBS) buffer (Tris 10mM, NaCl 150mM) 
supplemented with 0.1% Tween 20 (TBST) and 5% non-fat dry Milk (MTBST). Incubation 
with primary antibodies (see section 2.1.4.1) was performed in MTBST overnight at 4°C. The 
next day, membranes were washed three times with TBST followed by incubation with 
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secondary antibodies (see section 2.1.4.2) diluted in MTBST for 1 hour at room temperature. 
After three additional washing steps, chemiluminescent substrate was added and 
chemiluminescent signals were detected on a Fujifilm LAS4000 Imager. 
2.2.2.4 Preparation of immunoaffinity columns 
NS5A, Htra1 and Gpc2 antibodies were desalted on Zeba columns following Pierce's 
instructions and diluted in PBS to reach a concentration of 1 mg/ml. Antibodies were then 
coupled to 1 ml of Bio-Rad Affi-Gel 10 agarose beads (pre-washed in ice cold water and 
equilibrated in PBS) for 3 hours at 4 °C with gentle rotation. Coupling efficiency was 
determined with a Bradford assay comparing pre-coupling antibody versus post-coupling 
supernatant. Unreacted binding sites were blocked by the addition of 0.2 M ethanolamine in 
PBS for 3 hours at 4°C with gentle rotation. Beads were finally washed four times with cold 
PBS, re-suspended in 1 ml PBS (50% slurry) and stored at 4 °C. 
2.2.2.5 Immunoprecipitation and immuno-competitive capture 
Affi-gel beads with immobilized NS5A, Gpc2 or Htra1 (40 µl of suspension corresponding to 
20 μl of beads) were washed, equilibrated in cold cell lysis buffer and centrifuged 30 sec at 
3’000 g. After discarding supernatant, beads were incubated 1-3 hours with cell lysates at 4 °C 
with gentle rotation, washed four times with lysis buffer and eluted with non-reduced SDS 
sample buffer 10 min at 65°C. Beads were centrifuged 1 min at 3’000 g and reducing agent 
(DTT, 50 mM final) was added to the supernatant followed by 5 min heating at 85°C. For 
competition experiments, cell lysates were pre-incubated with increasing amounts of free 
antibodies for 1-3 hours at 4°C before being loaded onto Affi-gel immobilized antibodies 
according to Table 2.6. 
Study Number of concentration Concentrations (μg/ml) Number of replicates 
NS5A 12 0, 0.6, 1, 1.7, 2.9, 5, 8.5, 
14.5, 24.6, 41.9, 71.2, 121 
1 
Gpc2 5 0, 1, 2.5, 5, 10 3 
Htra1 5 0, 1, 2.5, 5, 10 3 
Table 2.6: Competitive-binding conditions. Concentrations of free antibody and number of replicates. 
2.2.2.6 Htra1 and C1QTNF5 recombinant expression and co-immunoprecipitation 
Recombinant expression of Htra1 and C1QTNF5 in Hek293 cells and co-immunoprecipitation 
experiments were performed at the Natural and Medical Sciences Institute (NMI) in Tübingen 
by Philipp Kaiser. Briefly, Hek293 cells were transiently transfected with HtrA1-pTag (52.7 
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kDa) and Tubulin-EGFP (77.6 kDa) prior to lysis and immunoprecipitation with BC2-Trap 
(immunoprecipitation of HtrA1-pTag). Immunoblots were generated using either gene- or tag-
specific antibodies. 
2.2.2.7 ASO pull-downs and competitive assays 
100 pmol of biotinylated IRE, AR, ESE2, ASO-A, ASO-B, ASO-C and ASO-D were coupled 
to 50 ul of nucleic-acid compatible streptavidin magnetic beads (supplied at 10 mg/ml) 
according to the manufacturer’s instructions. Briefly, magnetic beads were washed in 50 µl 
Tris HCl 20 mM pH 7.5, equilibrated in 50 µl of Tris HCl 20 mM pH 7.5, 1M NaCl, 1mM 
EDTA and incubated with biotinylated oligos for 30 min at room temperature under agitation. 
Beads with immobilized oligos were equilibrated in lysis buffer containing RNase inhibitor 
and incubated with cell extracts at 4°C for 1 hour under agitation. Flow-through samples were 
collected and beads were washed three times with cell lysis buffer. Elution was performed by 
adding SDS sample buffer containing DTT 5 min at 85°C. For competition experiments, cell 
lysates were pre-incubated for 1 hour with increasing amounts of free oligos in triplicates prior 
to be loaded on streptavidin immobilized oligos. 
2.2.2.8 In-gel digestion and peptide extraction 
Gel bands of maximum 1 cm were cut with a scalpel. Each band was further cut in squares of 
≈ 1 mm x 1 mm and loaded in wells from perforated or filter based 96 well plates. For protein 
in-gel digestion, an adapted protocol of Shevchenko and colleagues [46] was used. Proteins 
were reduced with 50 mM DTT in 100 mM ammonium bicarbonate for 1 hour at room 
temperature and alkylated with 55 mM IAA in 100 mM ammonium bicarbonate for 30 min at 
room temperature in the dark. 50 ng of trypsin in 10% acetonitrile/50 mM ammonium 
bicarbonate was added per well. Digestion was performed overnight at room temperature. 
Peptides were extracted twice with 1:2 (v/v) acetonitrile/25 mM ammonium bicarbonate, and 
twice with 1:2 (v/v) acetonitrile/5% formic acid, each steps for 15 min at room temperature. 
Peptides were dried down using a speedvac, and stored at −20°C before analysis.  
2.2.2.9 In vitro NS5A phosphorylation 
Recombinant NS5A Δ32 (BK strain, residues 33–447) was expressed in Escherichia coli and 
isolated from the soluble fraction as reported (30). The purified protein (2 μg) was premixed 
with 500 ng active human LATS2 (residues 480–1088) in kinase activity buffer (12.5 mM β-
glycerol phosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM EDTA, 0.25 mM DTT in 25 mM 
MOPS pH 7.2). The reaction was initiated by the addition of 1 mM ATP (15 μl reaction 
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volume), kept at 30 °C for 0, 20 and 120 min, and stopped by the addition of SDS sample 
buffer. Proteins were separated by SDS-PAGE and stained with Pro-Q Diamond and SYPRO 
Ruby. The same experiment was repeated with 400 ng of purified protein and 400 ng LATS2 
for 0, 20, 40, 60, and 80 min and processed for LC-MS analysis as described in section 2.2.2. 
 
2.2.3 Molecular biological methods 
2.2.3.1 Transient Replicon Assay 
At formerly Roche Nutley (Sophie Le Pogam and Sailaja Sankabathula), transient wild type 
replicon Con1 (expressing firefly luciferase reporter gene) (16) was used to introduce the 
Ser71Ala mutation in the NS5A region using Quick Change site-directed mutagenesis kit 
following manufacturer's instructions (Stratagene, La Jolla, CA). The introduced mutation was 
confirmed by DNA sequencing. Lunet Huh7 cells (4 × 10E6) were transfected with 10 μg of 
in vitro transcribed HCV transient subgenomic replicon RNAs (16) (WT or NS5A mutant). 
The normalized replication efficiency of the NS5A Ser71Ala mutant was determined as the 
firefly luciferase signal at 96 hours post-transfection divided by the signal at 4 hours. The 
replication capacity of the NS5A Ser71Ala mutant replicons was expressed as its normalized 
replication efficiency compared with that of the WT replicon set at a value of 100%. Average 
and standard deviation were calculated from four independent experiments. 
2.2.3.2 siRNA Knockdown Experiments 
All siRNA experiments were performed at Roche Nutley (Sophie Le Pogam and Sailaja 
Sankabathula) and all siRNAs used in the study were obtained from Integrated DNA 
Technologies, Inc., Coralville, IA. Transfection of siRNA in the HCV replicon cells was 
performed using Lipofectamine RNAiMAX (Invitrogen) following the manufacturer's 
protocol. 5’000 replicon cells, seeded in a 96 well plate 24 hours pre-siRNA transfection, were 
transfected in duplicate with 1 pmol of siRNA. The level of knockdown for each siRNA used 
in the study was evaluated by real-time PCR (17). Briefly, total cellular RNA was extracted 
with RNeasy (Qiagen, Venlo, Netherlands) according to manufacturer's instructions. Reverse 
transcription was carried out using the Taqman RT reagents (Applied Biosystems, Foster City, 
CA). To quantitate the level of HCV replicon, cDNA was amplified using Taqman Universal 
PCR mix (PE Biosystems, Norwalk, CT) with a set of primers and probe complementary to a 
region of the NPTII gene (fluorogenic probe labeled with FAM (6-carboxyfluorescein), 5′-
TCC TGC CGA GAA AGT ATC CAT CAT GGC T-3′; forward primer, 5′-GCT GCT ATT 
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GGG CGA AGT G-3′; reverse primer, GCC GCC GCA TTG CA; all obtained from Integrated 
DNA Technologies, Inc.). A second set of primers and probe complementary to the β-actin 
gene (Applied Biosystems) was used to quantitate the β-actin mRNA level as the endogenous 
control. For the quantitation of PI4KA, LATS1 and LATS2, sets of primers and probes 
(Applied Biosystems) were used according to the manufacturer's instructions. Level of 
knockdown for each target gene was normalized to the one obtained using negative control 
siRNAs. Replicon renilla luciferase signal was read 72 hours post-siRNA transfection using 
the Renilla Luciferase Assay System (Promega, Fitchburg, WI, USA) following the 
manufacturer's protocol. The signal for each gene-specific siRNA experiment was normalized 
to the one obtained using negative control siRNAs. Average and standard deviation were 
calculated from 8 to 12 independent experiments. 
2.2.3.3 Antisense oligonucleotides synthesis 
ASO-A was synthesized and biotinylated at Roche Innovation Center Copenhagen. ASO-B 
and ASO-C were synthesized and biotinylated (3’ biotin TEG, LGC, Biosearch Technologies) 
by Adrian Schäublin at Roche Innovation Center Basel using a MerMade 12 synthesizer from 
BioAutomation. ASO-D, MOD ASO-D and biotinylated ASO-D were obtained from 
Microsynth. 
 
2.2.4 LC-MS/MS analysis and data processing 
2.2.4.1 LC-MS/MS Analyses (NS5A and Gpc2) 
Dried samples were reconstituted in 2% acetonitrile/5% formic acid and analyzed with a 
nanoflow ultrahigh pressure liquid chromatography Easy-nLC system (Proxeon, Odense, 
Denmark) connected to Orbitrap LTQ Velos mass spectrometer (Thermo Fisher Scientific, 
Bremen, Germany). Peptides were concentrated on an AQUA C18 trap (100 μm × 10 mm, 
Phenomenex, Torrance, CA) before being separated on a ReproSil-Pur C18-AQ (75 μm × 200 
mm, 3 μm particle size, 120 Å, Dr. Maisch GmbH, Ammerbuch-Entringen Germany) analytical 
column using a 50 min gradient of 0–35% acetonitrile (with 0.6% acetic acid) at 250 nl/min. 
Acquisitions were cycled between full scan at 60,000 resolution (at m/z 400) in the Orbitrap 
and 10 data-dependent collision-induced dissociation scans in the ion trap. Full-scan MS was 
recalibrated on the fly using the polycyclodimethylsiloxane at m/z 445.120084 as a lock mass 
[47]. Ions were selected only with assigned charge states >1+ and then excluded for 30 s. 
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2.2.4.2 LC-MS/MS Analyses (Htra1,SMN, ASO pull-downs)  
Samples were reconstituted in 2% acetonitrile/5% formic acid and analyzed with a nanoflow 
ultrahigh pressure liquid chromatography Easy-nLC system (Proxeon, Odense, Denmark) 
connected to Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific, Bremen, 
Germany). Samples were concentrated on an Acclaim PepMap C18 trapping column (100 μm 
× 20 mm, 5 μm particle size) and peptides were separated on an Acclaim PepMap C18 EASY-
spray column (75 μm × 500 mm, 2 μm particle size) using the following gradient at 300 nl per 
min: 7–50% B in 45 min, 50–80% B in 2 min, 80% B for 13 min, corresponding to a total time 
of 60 min (buffer A: 0.1% formic acid; buffer B: 0.1% formic acid/acetonitrile). Data were on-
the-fly recalibrated using ambient air hexacyclodimethylsiloxane at m/z 445.1200238. The ten 
most intense precursor ions, with charge states between 2 and 6, a minimum intensity of 5E3, 
were monoisotopically selected for higher-energy collisional dissociation, using a quadrupole 
isolation of m/z 0.7, automatic gain control target of 1E4, maximum IT of 35 ms, collision 
energy of 30%, and ion trap readout with rapid scan rate. Only a single charge state per 
precursor was selected for MS2. Interrogated precursor ions were dynamically excluded for 75 
s using a ±10 ppm mass tolerance.  
2.2.4.3 Data processing (NS5A and Gpc2) 
MS raw files were converted into .dta files using Extract-MSn (version 1.0.0.8) and data 
searched using Sequest (version 27.0, revision 12, both Thermo Fisher Scientific). A database 
consisting of the human part of the SwissProt (June 2009, 34,275 entries, including splice 
variants) was used and was augmented with the five viral nonstructural proteins from the Con1 
replicon NS3, NS4A, NS4B, NS5A, and NS5B for NS5A interactome. Searching parameters 
were trypsin (full) as an enzyme, one missed-cleavage and a mass tolerance of 10 ppm, and 1.0 
Da for precursor and fragment ions, respectively. Oxidized methionines (+15.9949 Da), 
phosphorylated serine, threonine, and tyrosines (+79.9663 Da) were set as differential, while 
carbamidomethylated cysteines (+57.0215 Da) were set as static modifications. The spectral 
false discovery rate (specFDR) was restricted to 2.5% or 1.0% by performing a target-decoy 
search using a concatenated decoy database [48]. Processing and analysis, as described below, 
was performed with the 2.5% specFDR dataset, and the final protein-binding partners were 
verified with the 1.0% specFDR search. Data from NS5A in vitro phosphorylation experiment 
were processed using Proteome Discoverer (version 1.2) with the same parameters mentioned 
above and selected extracted ion chromatograms (EICs) generated with XCalibur's Qual 
Browser (Thermo Fisher Scientific). 
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2.2.4.4 Data processing (Htra1,SMN, ASO pull-downs) 
MS raw files were imported using Progenesis QI 2.1 (Nonlinear Dynamics; Newcastle, UK) 
and ions m/z were aligned to compensate for drifts in retention time between runs (maximum 
charge state set at +5). Peptides were identified by searching with Mascot Server 2.5.1 (Matrix 
Science, London, UK) together with the UniProt/SwissProt human or mouse protein database 
using trypsin/P as an enzyme (cleavage at carboxyl side of lysine or arginine also if a proline 
follows), a maximum of two missed cleavage sites, 10 ppm, and 0.5 Da as the precursor, and 
fragment ion tolerances, respectively. Carbamidomethylated cysteines (+57.02146 Da) were 
set as static while oxidized methionines (+15.99492 Da) were set as dynamic modifications. 
The specFDR was restricted to 1.0% by performing a target-decoy search using a concatenated 
decoy database.  
2.2.4.5 Statistical analysis 
Peptide extracted ion counts (EICs) were estimated as measure of peptide quantitation. Data 
normalization was performed in Progenesis by applying a scalar multiple to each feature 
abundance measurement with the assumption that most peptide ions do not change in 
abundance (similar abundance distributions globally). 
Normalized log2 scaled EIC was summed to calculate the relative protein abundance. In order 
to control quality, data were subjected to principal component analysis in Progenesis. In order 
to detect dose–response relationships, a linear model was then fit using a set of contrasts [49]. 
The contrasts were used to compare the protein abundance values above and below each 
concentration point. Then the maximum of the contrasts moderated t-statistics [50] was 
obtained for each protein. Multiple testing adjusted significance (p-values) was derived by 
permutation testing. Proteins with lowest adjusted p-values and highest signal reduction were 
considered as specific binders. Data computations and visualizations were performed with R 
(http://www.r-project.org/). 
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3. RESULTS 
 
The aim of this work was to develop a platform to screen endogenous protein-protein 
interactions (PPIs) in an unbiased fashion. Such an in vivo like global proteomics profiling can 
be achieved by combining affinity purification with mass spectrometry (AP-MS). However, 
this often results in an extensive list of potential interactors including many non-specific 
binders. To improve the specificity of the established AP-MS technique, a new approach was 
assessed in which protein extracts are pre-incubated with increasing concentration of free 
antibody prior to immunoprecipitation (IP) of the target protein with the same antibody 
immobilized on agarose beads (Figure 3.1). This proteome-wide platform was named Immuno-
Competitive Capture Mass Spectrometry (ICC-MS) and its rationale is based on the hypothesis 
that the capture of the target protein (the bait) as well as its interacting partners (the preys) 
should be gradually reduced upon increasing concentrations of the free form of the antibody, 
offering an innovative way to filter out non-specific binders. 
Technically, cellular lysates are incubated with competitive free antibody prior to IP. Proteins 
bound to immobilized antibodies and/or the matrix are eluted, digested by trypsin and further 
processed for analysis by nanoflow liquid chromatography-tandem mass spectrometry 
(nanoLC-MS/MS). After protein identification, MS data are normalized and relative protein 
abundances are translated from peptide extracted ion chromatograms (EICs). For downstream 
analysis, the relative abundance is plotted versus the increasing amounts of free target-specific 
antibody to obtain a concentration-dependent displacement profile. As previously postulated, 
the displacement of the target protein should be similar to the one from its interacting partners, 
which are extracted from the entire proteome by applying a robust statistical approach 
analyzing dose dependent relationships. 
ICC-MS specificity as well as its ability to deliver a short list of potential interactors having a 
high probability to be functionally relevant, have been evaluated in three experimental settings. 
In this thesis ICC-MS was first applied to study the interactome of the viral non-structural 
protein 5A (NS5A), a key regulatory protein of hepatitis C virus (HCV), in a cellular HCV 
replication system (Results 3.1.1). The approach was further assessed to identify interacting 
partners of the cell surface proteoglycan protein Glypican-2 (Gpc2) in differentiated neural 
progenitor cells (Results 3.1.2). Finally, the interactome of HtrA1, a protease described to be 
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associated with Age-related macular degeneration (AMD), was studied in retinal pigmented 
epithelial cells (Results 3.1.3). In the three experimental conditions, a comprehensive 
evaluation was performed to check whether ICC-MS applied in relevant cellular systems can 
be used to reliably identify interacting partners leading to a better understanding of the 
biological function of the target proteins. 
To expand the field of application of ICC-MS, the approach was in a second stage adapted to 
study interactions between proteins and oligonucleotides. Thus, the immobilized capture 
antibody was replaced by a specific oligonucleotide sequence and protein captures were 
competed by increasing concentrations of free forms of the same oligonucleotide sequence. 
After a feasibility assessment on well-described RNA-protein complexes (Results section 3.2.1 
and 3.2.2), the approach was applied to analyze the particular mode of action of a splicing 
modifier (Results section 3.2.3) and to explore potential mechanisms behind antisense 
oligonucleotides (ASOs) toxicity (Results section 3.3). 
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Figure 3.1: Schematic outline of the ICC-MS experimental procedure to identify protein 
interactors. Protein extracts are first pre-incubated with increasing concentrations of the free form of 
a protein-specific antibody. Extracts are then individually immunoprecipitated using the same antibody 
immobilized on agarose beads. The unbound fractions are discarded and beads are washed several 
times. Bound proteins are eluted from the beads and digested with trypsin. Extracted peptides are 
analyzed by LC-MS/MS on an Orbitrap mass spectrometer. Peptide extracted ion chromatograms 
(EICs) are summarized into relative abundance for each corresponding protein quantitation group. 
Concentration-dependent signal decrease of a specific interactor is finally detected by applying a robust 
statistical analysis. 
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3.1. Immuno-Competitive Capture Mass Spectrometry (ICC-MS) to study 
proteome-wide binding to proteins of interest 
3.1.1 Characterization of NS5A protein interactome in a cellular model of 
hepatitis C virus replication 
The first application of ICC-MS was dedicated to test its ability to identify novel and biological 
relevant interacting partner(s) of the viral NS5A protein. 
Worldwide approximately 71 million people are chronically infected with HCV as reported by 
the World Health Organization [51]. Chronic HCV infection can lead to fibrosis, cirrhosis, and 
often hepatocellular carcinoma. NS5A is a multi-faceted regulatory protein encoded by HCV 
which plays a key role in both genome replication and modulation of host response [52]. 
Direct interactions of NS5A with host proteins, such as phosphatidylinositol 4 kinase III alpha 
(PI4KA) and 33 kDa vesicle-associated membrane protein-associated protein A (VAPA), have 
been described and are required to support viral genome replication [53, 54]. Other NS5A-
interacting proteins have also been identified using Y2H [55] or classical co-expression and 
co-IP methods [56], but mostly in a setting where viral genome replication was absent. 
Exploring the complete NS5A interactome in a cellular HCV replication model using a MS-
based approach should lead to a better characterization of its function. 
In this context, ICC-MS was performed in Con1-Huh7, a human hepatocyte-derived cellular 
model containing the HCV subgenomic replicon, where active viral genome replication occurs 
[42]. In this experimental system, nonstructural HCV proteins NS3/NS4A, NS4B, NS5A, and 
NS5B are expressed at physiological levels and all steps of viral RNA replication are 
recapitulated. The cell model was provided by Junjun Gao (former Hoffmann-La Roche site in 
Nutley). 
A prerequisite, as for any antibody-based approach, was to use an antibody with high selectivity 
and sufficient capture efficiency. The anti-NS5A H26 antibody with an epitope mapped to 
NS5A amino-acid sequence 228-278 has been selected for evaluation. Sequence alignment 
using BLAST did not identify sequence similarities that would lead to potential cross-reactivity 
and anti-NS5A H26 antibody was then tested to precipitate NS5A from protein extracts of 
Con1-Huh7 cells (Figure 3.2 A). The lysis buffer was containing a low concentration of non-
denaturating detergent (0.5% NP40) to favor proteins solubilization while preserving their 
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native conformation and protein interactions. NS5A was captured with high efficiency (no 
signal detected in the unbound fraction) and high specificity (no signal detected after 
precipitation from the parental Huh7 cell line which does not express NS5A). To provide 
further support towards anti-NS5A H26 antibody specificity, an immunoblot of Con1-Huh7 
lysates where anti-NS5A H26 antibody was used as primary detection antibody was performed 
(Figure 3.2 B). In Con1-Huh7 lysate, a clear band was detected at the molecular weight of 
NS5A and cross-reactivity to other proteins can be reasonably excluded. 
 
Figure 3.2: Immunoblot-based validation of NS5A-antibody H26 specificity. (A) Con1-Huh7 and 
Huh7 cell lysate (20 µg) were probed for NS5A by immunoblot using anti-NS5A clone 7D4. Unbound 
and bound fractions from IP experiments performed using H26 antibody in both Con1-Huh7 and Huh7 
parental cell line extracts were probed for NS5A as well. (B) Detection of NS5A in Con1-Huh7 (10 µg) 
using H26 antibody. Recombinant NS5A (rNS5A) was loaded as a reference (NS5AΔ32 BK strain 
residues 33-447). 
In a next step the feasibility to introduce a competition between the free form and the 
immobilized form of NS5A antibody H26 was assessed by running a pilot experiment with five 
different concentrations of free antibody (Figure 3.3). Data obtained for the NS5A immunoblot 
confirmed that the free antibody prevents binding of the target protein to the immobilized 
capture antibody. Already with 3 µg/ml, the signal of the immunoprecipitated NS5A protein 
was reduced and the largest drop was observed when incubating with 9 µg/ml. This signal was 
then barely detectable after a pre-incubation of the lysate with 100 μg/ml of NS5A-specific 
antibody. 
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Figure 3.3: NS5A immunoblot from bound and unbound fractions from immuno-competitive 
precipitations in Con1-Huh7 lysates. 230 µg of cell extracts were pre-incubated with 0, 3, 9, 30 or 
100 µg/ml of free anti-NS5A H26 antibody before immunoprecipitation with anti-NS5A H26 antibody 
immobilized on agarose beads. (A) 8.5 µl from 100 µl total elution (B) 20 µg equivalent of Flow-
through, were probed for NS5A in an immunoblot. Input: Con1-Huh7 lysate, rNS5A: Recombinant 
NS5A (NS5AΔ32 BK strain residues 33-447). 
 
To generate a higher-resolved displacement profile in order to increase the probability 
identifying a limited number of highly specific interactors, the number of concentrations of 
free antibody was increased and samples were analyzed by LC-MS/MS. Thus twelve 
concentrations of free NS5A antibody were selected. According to the results of the pilot with 
five concentrations, additional concentrations were selected below 3 µg/ml and between 3 
µg/ml and 9 µg/ml. A concentration of 0.6 µg/ml was selected as the first one and then an even 
interval of 1.7 was applied (Figure 3.4). Bounds fractions were separated on SDS-PAGE 
(Figure 3.4 A), which was cut into four gel slices followed by in-gel digestion and further 
processed for protein identification by LC-MS/MS (2 injections, i.e. a total of 96 LC-MS/MS 
measurements). After data quality control of identified peptide peaks, extracted ion counts 
(EIC, log2 scaled) were normalized and summarized to relative protein abundance. A linear 
model was fit using a set of contrasts comparing the protein abundance values above and below 
each concentration point [49] to extract proteins displaced with increasing concentration of free 
anti-NS5A antibody. The maximum of the contrasts moderated t-statistics was obtained for 
37 
 
each protein [50] and permutation testing was applied to generate multiple testing adjusted 
significance (p-values). The MS output obtained when Jens Lamerz (Roche Innovation Center 
Basel) applied the above mentioned statistical analysis extracting dose-response relationships 
perfectly matched the corresponding immunoblot (Figure 3.4 B and C). 
In addition to the correlation between the immunoblot and the LC-MS/MS output, the target 
protein NS5A was ranked as the best hit (adjusted p value of 6.7 x 10-6) and low technical 
variance for replicate analyses was observed. Altogether, it validated the use of label-free 
quantitative MS as a reliable readout for ICC-MS experiments. 
 
Figure 3.4: ICC-MS of NS5A in Con1-Huh7 cell extracts. NS5A was immunoprecipitated from 
Con1-Huh7 cell lysates (300 µg total protein) which were pre-incubated with 0, 0.6, 1, 1.7, 2.9, 5, 8.5, 
14.5, 24.6, 41.9, 71.2 or 121 µg/mL of free NS5A antibody. (A) Bound fractions (25 µL from 60 µL 
elution volume) were separated by SDS-PAGE migrated half its length and proteins were stained with 
Coomassie blue. Four bands (from 20 to 150 kDa) were cut and in-gel trypsin digested for protein 
identification by LC-MS/MS. (B) NS5A protein in bound fractions was probed by Western Blot. (C) 
NS5A protein in bound fractions was identified and quantified by LC-MS/MS. Displacement curves 
obtained after statistical analysis performed by Jens Lamerz, Roche Innovation Center Basel (y axis: 
relative abundance; x axis: free NS5A antibody concentrations; replicates: red and blue). 
 
In total 769 proteins were identified and quantified in the NS5A-specific antibody bound 
fraction [57]. Among those proteins, only ten were highlighted as having a significant 
displacement upon increasing free NS5A-specific antibody concentrations (with adjusted p 
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values below 5%): NP1L4, PKHG2, FBW1B, NP1L1, PI4KA, UBP19, VAPA, LATS1, 
LATS2 and PGAM5 (Figure 3.5 and Table 3.1). 
 
Figure 3.5: Statistically significant NS5A interactors identified by ICC-MS of NS5A in Con1-
Huh7 cell extracts. Candidates are ranked by increasing adjusted p value (replicates: red and blue). 
 
Of the obtained list of interactors, few candidates were already described in the literature as 
NS5A host interacting proteins. Notably, PI4KA was previously described as being required 
for optimal HCV replication and as a direct interactor of NS5A leading to its activation [53]. 
VAPA was described to play a role in the formation of the HCV replication complex and to 
co-localize with NS5A in membrane lipid rafts [54]. NP1L1 and UBP19 were also already 
reported as potential interactors [58, 59]. The identification of these previously described 
binding partners indicate that ICC-MS is suitable to identify specific binders while efficiently 
filtering out non-specific ones. 
39 
 
Other candidates were much less convincing such as PKHG2, FBW1B and PGAM5 whose 
identifications were based on one peptide only (the latter having in addition a limited signal 
reduction below 50%). 
SwissProt entry Gene 
name 
pAdj Signal 
reduction 
[%] 
Total 
peptides 
Unique 
peptides 
NS5A_POLG_HCVCO  6.7E-06 99 41 13 
NP1L4_HUMAN NAP1L4 6.7E-06 95 9 6 
PKHG2_HUMAN PLEKHG2 6.7E-06 100 1 1 
FBW1B_HUMAN FBXW11 3.2E-04 100 1 1 
NP1L1_HUMAN NAP1L1 8.0E-04 90 10 5 
PI4KA_HUMAN PI4KA 3.1E-03 100 10 7 
UBP19_HUMAN USP19 3.4E-03 99 18 11 
VAPA_HUMAN VAPA 5.6E-03 86 7 2 
LATS1_HUMAN LATS1 1.8E-02 99 10 7 
LATS2_HUMAN LATS2 2.0E-02 100 4 4 
PGAM5_HUMAN PGAM5 3.5E-02 43 1 1 
Table 3.1: NS5A interacting candidates identified after statistical analysis of MS data. pAdj: p 
value adjusted by the Westfall-Young approach; Signal reduction: Signal difference between the highest 
and lowest concentration of free antibody; Total peptides: number of signals including different charge 
states; Unique peptides: number of peptides assigned to a protein quantitation group. Candidates ranked 
by increasing adjusted p-values. 
Interestingly, two candidates were never reported in the literature; the two members of the 
nuclear Dbf2-related (NDR) family of AGC kinases, [60, 61], LATS1 and LATS2. 
NS5A phosphorylation status was previously described to play an important role in HCV RNA 
replication without being completely understood [62-64]. NS5A has been indeed reported to 
be phosphorylated at multiple sites but the responsible upstream host kinase(s) remain largely 
unidentified, except for casein kinase I and II [65, 66]. 
LATS Ser/Thr kinases are known to phosphorylate a specific substrate consensus sequence 
His-X-Arg/His/Lys-X-X-Ser/Thr. This motif could be mapped in domain 1 of NS5A (His65 to 
Ser/Thr71) and was found to be highly conserved among all HCV viral genotypes (GT 1a, 1b, 
2a, 2b, 3a, 4a, 5a and 6a; Table 3.2) with Ser/Thr at position 71 100% conserved. 
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Observed residues in genotype (counts/percentage) 
Position GT 1a GT 1b GT 2a, b GT 3a GT 4a GT 5 GT 6 
66 His 
330/100 
His 
382/99.74 
Arg 
1/0.26 
His 
24/61.54 
Asn 
14/35.90 
His 
34/100 
His 
15/100 
His 2/100 His 
15/100 
67 Val 
330/100 
Val 
381/99.48 
Phe 
2/0.52 
Val 
39/100 
Val 
34/100 
Ile 
14/93.33 
Val 1/6.67 
Val 2/100 Val 
15/100 
68 Lys 
324/98.18 
Arg 
6/1.82 
Lys 
381/99.48 
Thr 1/0.26 
Arg 
1/0.26 
Arg 
39/100 
Lys 
34/100 
Lys 
14/93.33 
Lys 2/100 Lys 
15/100 
69 Asn 
326/98.79 
Thr 3/0.91 
Asn 
380/99.22 
Thr 3/0.78 
Met 
19/48.72 
Leu 
20/51.28 
Asn 
34/100 
Asn 
15/100 
Asn 2/100 Asn 
15/100 
70 Gly 
330/100 
Gly 
383/100 
Gly 
39/100 
Gly 
34/100 
Gly 
15/100 
Gly 2/100 Gly 
15/100 
71 Thr 
320/96.97 
Ser 9/2.73 
Ser 
383/100 
Thr 
24/61.54 
Ser 
15/39.46 
Ser 
34/100 
Ser 
15/100 
Thr 2/100 Thr 
13/86.67 
Ser 
2/13.34 
Table 3.2: His-X-Arg/His/Lys-X-X-Ser/Thr motif in NS5A across all HCV genotypes. Amino-acid 
alignment of 818 HCV clinical isolates (sequences collected from HCVdb at Los Alamos National 
Laboratory). 
The displacement of the capture of LATS1 and LATS2 over increasing concentrations of NS5A 
antibody have been also visualized on a western blot (Figure 3.6 A) and those co-captures were 
confirmed to take place only in the cell line expressing NS5A (Figure 3.6 B). To confirm LATS 
kinases as novel NS5A-interacting partners, additional co-immunoprecipitation (coIP) 
experiments were performed. Thus Con1-Huh7 as well as Huh7 extracts were 
immunoprecipitated using LATS1 and LATS2 antibodies. LATS1 and LATS2 were detected 
in the bound fractions of respectively LATS1 and LATS2 IP and NS5A was co-
immunoprecipitated in both experiments increasing the confidence towards LATS kinases as 
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being true NS5A-interactors (Figure 3.6 C). To check whether NS5A is a bona fide substrate 
of LATS kinases, an in vitro phosphorylation assay was performed. Catalytically active 
recombinant LATS2 (500 ng) was premixed with purified recombinant NS5A derived from E. 
coli (2 µg) and reaction was initiated by adding 1mM ATP. The reaction was stopped after 0, 
20 and 120 min. Phosphoproteins were then stained on SDS-PAGE with Pro-QDiamond and 
revealed that LATS2 kinases was inducing phosphorylation of NS5A already after 20 minutes 
of incubation (Figure 3.7 B; A: total protein staining using SYPRO). 
 
Figure 3.6: Binding confirmation of LATS1 and LATS2 to NS5A. (A) NS5A ICC-MS in Con1-
Huh7. 380 µg of cell lysates were incubated with 0, 0.6, 1, 1.7, 2.9, 5, 8.5, 14.5, 24.6, 41.9, 71.2 and 
121 µg/ml of free NS5A antibody prior to NS5A immunoprecipitation. 25 of 60 µl total elution were 
probed for LATS1 and LATS2. (B) NS5A IP in Con1-Huh7 and Huh7 parental cell line. NS5A, LATS1 
and LATS2 immunoblots (IB). (C) LATS1/2 IP in Con1-Huh7 cell line (330 µg protein extracts, 5.5 of 
60 µl total elution loaded) and NS5A IB (18 of 60 µl total elution loaded). 
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Figure 3.7: LATS2 is phosphorylating NS5A in vitro. NS5A purified recombinant protein (residues 
33-447) was mixed with recombinant LATS2 for 20 or 120min. Reaction was initiated by the addition 
of 1mM ATP. A negative control without kinase was included as well. (A) Total protein staining with 
SYPRO. (B) Phosphoprotein staining with Pro-Q Diamond. 
 
To identify the site of phosphorylation, the same experiment was repeated with recombinant 
NS5A (400 ng) incubated with LATS2 (400 ng) in presence of ATP for 0, 20, 40, 60 and 80 
min. LC-MS/MS analysis of reaction samples unambiguously localized the site of NS5A 
phosphorylation on Ser71, i.e. on the Serine of the consensus sequence. Semi-quantitative 
assessment of the phosphorylation stoichiometry was performed by comparing the peak areas 
of the unphosphorylated and the phosphorylated peptide (Figure 3.8) and revealed that after 80 
min of reaction, the phosphorylated peptide 69NGSMRIVGPK78 was almost nine times more 
abundant than its unmodified version. 
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Figure 3.8: NS5A Ser71 phosphorylation by LATS2. Relative quantitation of phosphorylated and 
unphosphorylated NGSMRIVGPK peptide by LC-MS/MS. Ratios of EICs represented. Error bars, S.E. 
2 replicates. 
To further assess the biological relevance of these findings, the impact of a point mutation 
preventing phosphorylation at Ser71 on Con1-Huh7 replication capacity was explored. At 
formerly Roche Nutley, Sophie Le Pogam and Sailaja Sankabathula introduced the Ser71Ala 
mutation by site-directed mutagenesis in the NS5A region of the wild type (WT) transient 
genotype 1b Con1 replicon, which expresses the firefly luciferase reporter gene. Replication 
efficiency was determined by the luciferase signal at 96 hours post-transfection divided by the 
signal at 4 hours and compared to the WT. Infecting Huh7 cells with Ser71Ala mutant replicon 
resulted in a clear impairment of viral replication capacity (only 14% compared with the WT 
replicon replication, Figure 3.9) suggesting that phosphorylation of Ser71 is essential for 
optimal viral genome replication. 
 
Figure 3.9: Replication capacity of Con1-NS5A-Ser71Ala. Normalized replication efficiency of 
mutant transient replicon compared with reference strain Con1-WT (set at 100%) (n=4). 
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In the same lab, the effect of siRNAs targeting LATS1 and LATS2 kinases were further 
evaluated by measuring the HCV replicon renilla luciferase signal (Figure 3.10). An inhibition 
of 63% and 38% respectively was detectable suggesting a relevant role for LATS kinases in 
HCV life cycle probably by modulating NS5A phosphorylation. 
 
Figure 3.10: LATS1 and LATS2 silencing. (A) Gene knockdown after siRNA transfection (as positive 
controls, Con1 HCV replicon sequence and PI4KA gene, n=5 to 9). (B) HCV replicon renilla luciferase 
signal inhibition normalized to negative control siRNA (n=8 to 12). 
The application of ICC-MS approach to identify novel interacting partners of the viral NS5A 
protein resulted in only a handful of potential interactors. The study revealed an implication of 
Ser71 phosphorylation in viral replication and that LATS kinases are probably important 
regulators of NS5A function.  
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3.1.2 Characterization of Glypican-2 protein interactome in a human neural stem 
cell model 
Next, the ICC-MS approach was applied to identify interacting partners of Glypican-2 (Gpc2), 
a cell surface proteoglycan recently discovered as a potential new marker of neurogenesis by 
Ducret et al. using an unbiased proteomics screen in a stem cell model of human brain 
development [43]. Glypicans (Gpcs) have been indeed described to regulate the activity of 
several growth factors involved in morphogenesis [67], nevertheless a functional role of Gpcs 
in adult neurogenesis has never been reported. 
Gpcs as part of Heparan sulfate proteoglycans (HSPGs) family are bound to the cell via a 
glycosylphosphatidylinositol (GPI) linkage (Figure 3.11). Six members exist in vertebrates, 
Gpc1-Gpc6 [68], with Gpc2 (or cerebroglycan) being exclusively expressed in central nervous 
system [69]. Heparan sulfate chains are highly negatively charged polysaccharides prone to 
interact with many proteins with a net positive charge but with little specificity. Nevertheless, 
extracellular matrix proteins such as chemokines, growth factors as well as their receptors were 
shown to have preferred HS binding structures indicating a higher specificity [70]. Heparan 
sulfate proteoglycans having a core protein with heparan sulfate chains and a kind of 
glycosaminoglycan, have been shown to be involved in signaling pathway regulation (Wnt 
Hedgehog, transforming growth factor-ß, fibroblast growth factor pathways) and synaptic 
organization [70-74] thus probably playing a crucial role in CNS development. 
 
Figure 3.11: Glypican structure. N-terminal domain is globular and stabilized by disulphide bonds. 
The core protein is linked to the cell membrane via a glycolipid anchor (glycosylphosphatidylinositol 
= GPI). Heparan sulphate chains are linear polysaccharides with alternating glucosamine and uronic 
acid residues. HS are carried at the N-terminal and varies in their modifications state, such as 
deacetylation or sulfation. Upon cleavage at GPI anchor, an HS proteoglycan is shed from the cell 
surface. 
GPI anchor
HS
Core protein
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Identifying proteins interacting with Gpc2 in a human neural stem cell model would lead to a 
better understanding of its potential link to adult neurogenesis. Consequently, ICC-MS was 
applied to filter out non-specific binders which in turn may facilitate the selection and the 
validation of true interactors. 
Five anti-Gpc2 antibodies generated in the lab of Jean-Philippe Carralot (Roche Innovation 
Center Basel) were tested for Gpc2 capture in H4 neuroglioma cells transfected with His-
tagged human Gpc2 (Figure 3.12, cells provided by Sebastian Lugert, Roche Innovation Center 
Basel). Clone 2/34 did not show a high yield of capture and with clone 2/38 additional bands 
were detected indicating a lower specificity towards Gpc2. Among the best performing 
antibodies, clone 2/43 was further selected to capture Gpc2 in a cellular model for 
neurogenesis. Neural progenitor cells (NPCs) were cultured by Sebastian Lugert under 
differentiating conditions for 21 days (d21NPCs). In the starting material (d21 NPC protein 
extract) and the bound fraction, the core protein was detected at a molecular weight of ~ 60kDa 
(Figure 3.13.) as well as a smear observed at higher molecular masses which might correspond 
to different sugar modification patterns. An additional band between 30 and 40 kDa was also 
detected which could correspond to a cleaved version of Gpc2. Indeed, proteolytic cleavages 
in the core or at GPI linkage are known to generate different Gpc forms [73]. In addition to the 
large diversity in Gpc structures, cleaved/uncleaved Gpc ratio among Gpc members and tissues 
are also varying [67]. 
A fraction of the bound fraction was separated by SDS-PAGE and further processed for LC-
MS/MS protein identification. As expected, Gpc2 was identified in the different bands (Table 
3.3) and enriched in band 3 to 6 with a C terminal peptide missing in the low molecular weight 
band accordingly to the assumption of a cleaved form. 
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Figure 3.12: Gpc2 immuno-capture in human Gpc2-transfected H4 cell extracts. Gpc2 was 
immunoprecipitated from Gpc2-transfected H4 protein extracts (220 µg) using anti-Gpc2 antibody 
clone 2/34, 2/38, 2/40, 2/42 or 2/43 immobilized on agarose resin (1 hour at 4°C). Western blot was 
probed with anti-penta His (619) antibody generated by Jean-Philippe Carralot. Loading: hGPC2 H4 
extract and unbound: 10µg; Bound: 2.7 µl from 60 µl elution; Bound +: 18.9 µl from 60 µl elution. 
 
Figure 3.13. Gpc2 immuno-capture in d21 NPC. Gpc2 was immunoprecipitated from d21NPC 
protein extracts (730 µg) using anti-Gpc2 antibody clone 2/43 immobilized on agarose resin (1 hour at 
4°C). Western blot revealed with clone 2/40. Loading: d21 NSCs and unbound: 50 µg; Bound: 4 µl 
from 60 µl elution; Bound +: 16 µl from 60 µl elution. 
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Table 3.3: Gpc2 LC-MS/MS identification in d21NPC Gpc2 immunoprecipitates. Eluate from 
Gpc2 immunoprecipitation in d21NPCs (18 µL) was separated by SDS-PAGE and stained by 
Coomassie blue. After in gel-digestion with trypsin, samples were processed for LC-MS/MS 
identification with a nanoflow Easy-nLC system connected to an LTQ-Orbitrap Velos mass 
spectrometer. Gpc2 was identified with 15, 22 and 20 unique peptides respectively in SDS-PAGE gel 
bands 3, 4 and 5/6. 
As previously mentioned, antibody specificity is a crucial prerequisite for the success of ICC-
MS experiments. In order to confirm the specificity of clone 2/43, a protein extract from d21 
NSC was probed using 2/43 as primary antibody (Figure 3.14). The clone 2/43 did not perform 
as well as 2/40 in immunoblot. No clear bands were detected but a smear was observed around 
60 kDa and at higher molecular masses. Even if it is corresponding to the size range of the core 
protein and of the different sugar modification patterns previously described, an unambiguous 
Gpc2 detection by clone 2/43 cannot be concluded from this experiment. This could be due to 
the fact, that 2/43 does not recognize a linear epitope. 
 
Figure 3.14: d21NPC extract probed with anti-Gpc2 clone 2/43. Anti-Gpc2 clone 2/43 was used to 
probe d21NPC protein extract (50µg). 
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Nevertheless, the superiority of clone 2/43 in terms of Gpc2-capture efficiency (Figure 3.12) 
was considered as the most important factor to use this antibody in an ICC-MS approach. 
A pilot experiment with seven different concentrations of competitor confirmed that a 
competition between free and immobilized anti-Gpc2 clone 2/43 was indeed happening in d21 
NSC protein extracts (Figure 3.15). Notably, a concentration of 0.5 µg/ml of free Gpc2 
antibody did not have an impact on Gpc2 capture. The largest drop was occurring with 5 µg/ml 
and a close to total displacement was achieved with 10 µg/ml. 
 
Figure 3.15: Gpc2 competitive immuno-capture in d21NPCs. Gpc2 capture from d21NPCs (570 µg 
protein extracts per conditions) pre-incubated with 0, 0.5, 1, 2.5, 5, 10 and 50 µg/ml of free Gpc2 2/43 
antibody was probed by Western blot with anti GPC clone 2/40. 
Based on these observations, the ICC-MS experimental design was slightly modified compared 
to 3.1.2., by decreasing the number of free antibody competitor concentrations to five and by 
increasing the number of replicates to three. Again the Western Blot image was matching the 
MS readout (Figure 3.16) and 5 different concentrations turned out to be sufficient to capture 
the displacement. 
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Figure 3.16: ICC-MS of Gpc2 in d21NPC extracts. Gpc2 was immunoprecipitated from d21NPC 
lysates (855 µg protein extracts per conditions) pre-incubated with 0, 1, 2.5, 5 and 10 µg/ml of free 
Gpc2 antibody. (A) Gpc2 protein in bound fractions was probed by Western Blot. (B) Gpc2 protein in 
bound fractions was identified and quantified by LC-MS/MS (y axis: relative abundance; x axis: free 
Gpc2 antibody concentrations; each black dot is a replicates; displacement curve from band 
corresponding to core protein). 
In total 512 proteins were identified and quantified in the Gpc2-specific antibody bound 
fraction. MS signals statistical analysis revealed fifteen proteins significantly displaced in 
addition to Gpc2 (pAdj below 1% and signal reduction above 50%, Table 3.4). 
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SwissProt entry pAdj Signal reduction (%) Peptides 
GPC2_HUMAN 0.000681533 92 19 
ECHB_HUMAN 0.000582401 90 22 
ECHA_HUMAN 0.000686401 90 46 
FGF2_HUMAN 0.000898094 89 1 
GSLG1_HUMAN 0.000970668 79 5 
SQSTM_HUMAN 0.000593186 79 2 
ACOT8_HUMAN 0.000585952 77 3 
HIC2_HUMAN 0.000706589 74 1 
LPPRC_HUMAN 0.000990681 74 5 
SGPL1_HUMAN 0.000589547 68 4 
TF3C1_HUMAN 0.001001001 60 1 
EIF3A_HUMAN 0.000980572 54 13 
EIF3D_HUAMN 0.000696349 53 7 
SRP14_HUMAN 0.000906567 53 2 
EIF3C_HUMAN 0.000691339 52 7 
EIF3L_HUMAN 0.000657592 51 5 
Table 3.4: Gpc2 interacting candidates identified after statistical analysis of MS data. pAdj: p 
value adjusted by the Westfall-Young approach; Signal reduction: Signal difference between the highest 
and lowest concentration of free antibody; peptides: number of peptides assigned to a protein 
quantitation group. Candidates were ranked by decreasing signal reduction. 
Identified Gpc2 interacting candidates are connected to different biological processes: lipid 
metabolism (ECHB, ECHA, SGPL1), translation (EIF3A, EIF3D, EIF3C, EIF3L), 
transcription (TF3C1, LPPRC, HIC2) and differentiation (FGF2, SQSTM). FGF2 was the only 
heparan binding growth factor from the list. Its displacement - although highly significant - 
was based on one peptide only, probably reflecting either the fact that Gpc2 is acting as a low-
affinity binding protein towards extracellular signaling molecules and/or that FGF2 is a small 
and a low abundant protein in NPCs extracts. Interestingly, a receptor in the FGF signaling 
pathway, GSLG1, was also identified (Table 3.4 and Figure 3.17 A). 
To confirm a direct binding of FGF2 to Gpc2, a reverse pull-down using FGF2 as bait was 
performed. Differentiated NPCs were immunoprecipitated using a FGF2 antibody and the 
bound fractions were probed for Gpc2 by immunoblot. Gpc2 was identified in the bound 
fraction of FGF2 IP (Figure 3.17) providing further support towards a true interaction between 
FGF2 and Gpc2. 
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Figure 3.17: Glypican-2 is specifically interacting with FGF2 and GSLG1 in d21NPC extracts. 
(A) FGF2 and GSLG1 showed a statistically significant concentration-dependent decrease in MS signal. 
(B) Gpc2 and FGF2 were co-captured in 21 days differentiated NSCs. Captures were displaced by pre-
incubation with free Gpc2 antibody (IP Gpc2 + compet Gpc2, 10 µg/ml). 
Notably, FGF2 has been previously described to play an important role in adult NPC 
proliferation [75-78]. It is also known from the literature that HSPGs are having either 
stimulatory or inhibitory effects on FGF2 depending on cell type. For example, an increased 
proliferative effect towards FGF was observed in keratinocytes [79] and an anti-proliferative 
effect has been described in morphogenesis [67]. It was also mentioned that an opposite activity 
can be observed depending on the type of growth factor. Thus FGF2 was an attractive candidate 
for additional follow up experiments. 
To assess the effect of Gpc2 on FGF2, hNPCs were co-cultured in Lugert’s lab in the presence 
of FGF2 in combination with increasing amounts of recombinant Gpc2 (Figure 3.18). The pro-
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proliferative effect of FGF2 turned out to be inhibited by the addition of Gpc2 in a 
concentration-dependent manner. Gpc2 could be potentially sequestering FGF2 to modulate 
the transition from proliferation to differentiation as described for Gpc1 in skeletal muscle 
where it prevent FGF2 interaction with transducing receptors [80]. 
 
Figure 3.18: GPC2 inhibits the proliferative effect of FGF2 which in return leads to 
differentiation Endogenous application of GPC2 inhibits FGF2 induced neural stem cell mitogenic 
activity. 
Gpc2 was found to be abundant in human cerebrospinal fluid (CSF) and markedly decreased 
in a longitudinal cohort of aging CSF [43]. Collectively, these results are strongly suggesting 
that Gpc2 could act as a niche factor involved in regulation of adult neurogenesis offering the 
potential to assess in a non-invasive manner the degree of neurogenesis in human physiology 
and disease. 
More than five hundreds proteins were initially identified in Gpc2 immunoprecipitates from 
dNPCs. By applying ICC-MS approach, only fifteen proteins were extracted from the 
background of non-specific binders. With such a limited number of candidates, FGF2 was 
rapidly identified as an attractive target for further follow-up experiments. This is another 
illustration of how ICC-MS led to successful identification of biologically relevant protein-
protein interactions. 
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3.1.3 Characterization of the HtrA1 protein interactome in a polarized retinal 
pigment epithelial (RPE) disease model 
HtrA1, part of the high-temperature requirement A (HtrA) family of serine proteases, has been 
reported to play an important role among other pathologies in the pathogenesis of Age-related 
macular degeneration (AMD), the primary cause of irreversible blindness in aging population 
[81]. HtrA1 is composed of four domains (Figure 3.19) including a highly conserved trypsin-
like protease domain. HtrA1 is referred as a secreted protease having a signal peptide for its 
secretion but an intracellular localization has been reported as well, both in the cytoplasm and 
the nucleus [82]. 
HtrA1 overexpression has been shown to lead to changes in the Bruch’s membrane (BM) in a 
transgenic mouse model by cleavage of extracellular matrix components (ECM) [83] and 
furthermore, elevated levels of HtrA1 have been reported in the retinal pigment epithelial 
(RPE) cells of patients genotyped for the AMD risk variant [81]. Still the correlation between 
HtrA1 levels and how RPE functions are affected is poorly understood and it is still unknown 
whether HtrA1 has an intracellular activity related to AMD. 
 
Figure 3.19: HtrA1 structural domains. HtrA1 protein has four distinct protein domains. From N- to 
C-terminus: IGFBP (insulin-like growth factor binding protein domain) - a kazal domain – active 
domain (trypsin-type serine protease) – PDZ (regulatory domain). SS: signal sequence (for secretion). 
More clarity about the intracellular role of HtrA1 and its association to AMD could be brought 
by the identification of HtrA1-interacting partners in a relevant cellular model. 
Thus ICC-MS was applied in a human fetal retinal pigment epithelial (hfRPE) cell culture 
model, in which cells are fully differentiated into a polarized functional monolayer and in 
which HtrA1 protein is overexpressed to a pathological level [44, 84]. Such a pertinent cellular 
model resembling the RPE layer in the retina tissue and mimicking the increase of HtrA1 
transcriptional levels associated with AMD predisposition and pathogenesis was successfully 
implemented in the lab of Roberto Iacone (Roche Innovation Center Basel) by Esther Melo, 
Frédéric Delobel and Corinne Stucki [44]. hfRPE cells were seeded and cultivated in transwell 
plates coated with laminin (Figure 3.20). After attachment and proliferation (one week), cells 
were transferred to a RPE maturation medium for three weeks. Differentiation into a polarized 
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functional monolayer was confirmed by RPE markers gene expression profiling [44]. After 
RPE monolayer formation, cells were stably transfected with a recombinant adenovirus 
containing wild type human HtrA1 mRNA (RPE HtrA1 WT) or an enzymatically inactive 
variant having a conversion by site-directed mutagenesis of the active domain Ser328 to 
Alanine (RPE HtrA1 S328A). Based on previous data generated by Esther Melo [85], the level 
of HtrA1 overexpression was assumed to be similar using HtrA1 WT or S328A constructs and 
in the range of tenfold higher compared to endogenous HtrA1 expression in untransfected RPE. 
 
Figure 3.20: Human fetal retinal pigment epithelial (hfRPE) cell culture model. hfRPE cells were 
seeded in transwells. (A) Apical medium (mimicking retina secretion) (B) Basolateral medium 
(mimicking choroid secretion) (C) Intracellular (Fetal RPE cells on laminin-coated membrane). 
Similarly to the previous applications, first the specificity of the commercially available anti-
HtrA1 monoclonal antibody (MAB2916) against HtrA1 was evaluated. Proteins were extracted 
from differentiated hfRPE untransfected or overexpressing HtrA1 with a detergent-based 
buffer in non-denaturant non-ionic mild conditions (1% NP40). HtrA1 was specifically 
immunoprecipitated by the selected anti-HtrA1 antibody in cells overexpressing HtrA1 (Figure 
3.21) whereas endogenous HtrA1 could not be detected due to low HtrA1 expression levels in 
the RPE cells. Notably, the capture antibody has also been used for immunoblot detection. In 
RPE lysates it detected in addition to HtrA1 (~ 50 kDa), a few high molecular bands. Those 
bands could represent HtrA1 aggregates as the protein has been described to form multimers 
[85]. Altogether, the performance of the antibody was considered to be sufficient for ICC-MS 
to further identify intracellular HtrA1 interacting partners. 
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Figure 3.21: HtrA1 immuno-capture in differentiated hfRPE. HtrA1 was immunoprecipitated from 
protein extracts of hfRPE differentiated for 21 days (900 µg), untransfected (RPE) or overexpressing 
HtrA1 (RPE HtrA1 WT) using anti-HtrA1 antibody (R&D MAB2916). Western blot was detected with 
the same antibody. Loading: soluble fraction of total protein extract from RPE and RPE HtrA1 WT: 50 
µg; Unbound: 50µg; Bound: 10 µl from 60 µl elution; Bound +: 15 µl from 60 µl elution. 
Immunoprecipitation with human IgG as a control as well as HtrA1 immunoprecipitation in absence of 
protein extracts (No RPE). 
ICC-MS (five concentrations of free anti-HtrA1 antibody in triplicates) was then performed 
both in 500 µg of soluble protein extracts from differentiated hfRPE either transfected with 
HtrA1 WT or the enzymatically inactive variant HtrA1 S328A. A similar capture and 
displacement upon increasing concentrations of HtrA1 antibody were observed for both 
transfections (Figure 3.22 A and B). 
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Figure 3.22: ICC-MS of HtrA1 in hfRPE extracts. HtrA1 was immunoprecipitated from 21 days 
differentiated hfRPE (500 µg protein extracts per conditions; both proteolytic active HtrA1 protein and 
enzymatically inactive S328A variant transfections) pre-incubated with 0, 1, 2.5, 5 and 10 µg/ml of free 
HtrA1 antibody. HtrA1 protein in bound fractions was (A) probed by Western Blot with an anti-HtrA1 
antibody [83] (B) identified and quantified by LC-MS/MS (y axis: relative abundance; x axis: free 
HtrA1 antibody concentrations; each black dot is a replicate). 
In total, 868 proteins were identified and quantified respectively in hfRPE overexpressing 
HtrA1 WT and among them nineteen proteins were identified as HtrA1-interacting proteins 
(adjusted p-value below 1% and at least two unique peptides; Table 3.5). 
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SwissProt entry pAdj Signal reduction (%) Unique Peptides 
HTRA1_HUMAN 0.0002 96 37 
C1QTNF5_HUMAN 0.0002 96 3 
TBB4B/1/8/8L_HUMAN 0.0002 85 2 
TBB3_HUMAN 0.0002 94 2 
ECHB_HUMAN 0.0002 75 4 
NPM_HUMAN 0.0004 98 5 
RS27/L_HUMAN 0.0005 85 4 
PGAM5_HUMAN 0.0005 72 4 
TBA1A/3C/3E/4A_HUMAN 0.0005 87 4 
COL12_HUMAN 0.0011 65 4 
DJC10_HUMAN 0.0039 92 3 
TBA4A_HUMAN 0.0055 97 2 
GCST_HUAMN 0.0063 66 2 
DNJA2_HUMAN 0.0064 86 3 
TBB5_HUMAN 0.0071 90 6 
TBB4A_HUMAN 0.0071 90 12 
TBB6_HUMAN 0.0071 94 4 
TBB4B/8/8L_HUMAN 0.0076 90 2 
TBB3/1_HUMAN 0.0081 91 12 
TBA1C/4B/AL3_HUMAN 0.0087 89 4 
 
Table 3.5: HtrA1 co-immunoprecipitated proteins after statistical analysis of MS data (ranked by 
pAdj then signal reduction). Besides proteins from the tubulin family, 9 proteins (C1QTNF5, ECHB, 
NPM, RS27L, PGAM5, COL12, DJC10, GCST and DNJA2) were identified as HtrA1-interacting 
proteins with adjusted p-values below 1% and at least 2 unique peptides. pAdj: p value to test 
displacement adjusted by the Westfall-Young approach; Signal reduction: signal difference between 
the highest and the lowest concentration of competitor antibody; Unique peptides: number of peptides 
of a respective protein quantitation group. 
Interestingly from the list, ten proteins were part of the tubulin family. Comparable 
interactions, predominantly with ß-isoforms, were observed when performing an ICC-MS in 
HtrA1 S328A hfRPE indicating tubulin binding irrespectively of the protease activity (Figure 
3.23). Similar observations describing HtrA1 as a microtubule associated protein (MAP) were 
already published [86, 87]. 
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Figure 3.23: ß-tubulins identification as specific HtrA1 interacting partners by ICC-MS. HtrA1 
was immunoprecipitated from 21 days differentiated hfRPE (500 µg protein extracts per conditions; 
both proteolytic active HtrA1 protein and enzymatically inactive S328A variant transfections) pre-
incubated with 0, 1, 2.5, 5 and 10 µg/ml of free HtrA1 antibody. HtrA1 protein in bound fractions was 
(A) probed by Western Blot with an in-house antibody (B) identified and quantified by LC-MS/MS (y 
axis: change in ß-tubulins log2 abundance; x axis: free HtrA1 antibody concentrations; each dot is a 
replicate). 
However, to confirm this interaction further validation experiments via co-IP in 21 days 
differentiated hfRPE overexpressing HtrA1 WT or HtrA1 S328A were performed (Figure 3.24 
A) as well as in cotransfected Hek293 cells (Figure 3.24 B, data generated at NMI by Dr Philipp 
Kaiser). Both approaches unambiguously confirmed tubulins as being specific HtrA1 
interacting partners. 
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Figure 3.24: HtrA1 interacts with tubulin (A) HtrA1 was co-captured in 21 days differentiated hfRPE 
overexpressing HtrA1 WT (RPE HtrA1 WT) and HtrA1 S328A (RPE HtrA1 S328A) 
immunoprecipitated with a ß-tubulin antibody (MAB3408). Inputs (10 µg cell lysates) and bound 
fraction (1/4 elution volume) revealed by either anti-ß-tubulin (Ab52623) or anti-HtrA1 (in-house) 
antibodies. (B) Hek293 cells were transiently transfected with HtrA1-pTag (52.7 kDa) and tubulin-
EGFP (77.6 kDa) prior to lysis and immunoprecipitation with BC2-Trap which specifically binds to the 
pTag. Immunoblots were probed with anti-ß-tubulin antibody (MAB3408) or anti-BC2 nanobody 
conjugated to Alexa647. Experiments are performed in biological replicates. Shown are representative 
results of one experiment. Control for unspecific binding to the nanobody scaffold and/or bead matrix: 
beads coupled with a BSA-specific nanobody (data generated at NMI by Dr Philipp Kaiser, material 
from ChromoTek). Additional negative controls indicated that interactions are not mediated by the 
interaction with beads loaded with EGFP or EGFP-pTag (data not shown). 
In addition to HtrA1 direct interaction with tubulins, subsequent degradation could then be 
demonstrated [44] in alignment with published literature [87] and supporting the hypothesis 
that HtrA1 is having an intracellular protease activity. 
In the list of HtrA1 interacting partners, candidates related to the described HtrA1 low 
temperature chaperone activity [88, 89] were also identified (i.e. DJC10 and DNAJ2) as well 
as interactors that were never reported in the literature such as Complement C1q tumor necrosis 
factor-related protein 5 (C1QTNF5). This latter is definitively an interesting candidate for 
further validation experiments as proteins of the complement system are at the basis of the 
development of AMD [90]. C1QTNF5 has been described as a component of basement 
membranes which may play a role in cell adhesion and interestingly mutations in this gene 
have been associated with late-onset retinal degeneration [91]. Intracellular binding confidence 
was further confirmed by coIP experiments (Figure 3.25 A and B). Although HtrA1-C1QTNF5 
interaction was also detected in the apical media from differentiated RPE using ICC-MS (data 
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not shown), this was not observed by immunoblot probably due to lower protein concentrations 
in the apical medium. 
 
 
Figure 3.25: C1QTNF5 interacts with HtrA1. (A) HtrA1 was co-captured in 21 days differentiated 
hfRPE overexpressing HtrA1 (RPE HtrA1 WT) and HtrA1 S328A (RPE HtrA1 S328A) 
immunoprecipitated with C1QTNF5 antibody (LS-C345051). IP were also performed in apical medium 
mimicking retina secretion (compartment A Figure 3.20). Inputs (10 µg cell lysates or 15 µl apical 
medium) and bound fractions (1/4 elution volume) revealed by either anti-C1QTNF5 (Sigma 
HPA038604) or anti-HtrA1 (in-house) antibodies. (B) Soluble protein extracts of Hek293 cells 
transiently expressing HtrA1-pTag (52.7 kDa) and C1QTNF5-EGFP (77.6 kDa) were incubated with 
the BC2-Trap [92] to precipitate HtrA1-pTag. Immunoblots were probed with tag-specific antibodies. 
Control for unspecific binding to the nanobody scaffold and/or bead matrix: beads coupled with a BSA-
specific nanobody (data generated at NMI by Dr Philipp Kaiser, material from ChromoTek). Additional 
negative controls indicated that interactions are not mediated by the interaction with beads loaded with 
EGFP or EGFP-pTag (data not shown). 
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In summary the results demonstrated that the ICC-MS approach was a relevant method to 
identify novel and biologically relevant Htra1-interacting partners. 
Taken together, the results obtained from all the above-mentioned applications support the 
validity of ICC-MS as a technically straightforward and widely applicable new approach for 
studying in an unbiased fashion biologically relevant protein-protein interactions (Figure 3.26). 
Notably, the combination of immuno-competition and quantitative mass spectrometry 
increases specificity compared to more classical AP-MS approaches by efficiently filtering out 
background proteins. Without the need for prior knowledge, a shorter list of candidates is 
generated having a greater chance to be functionally validated. 
 
Figure 3.26: Schematic overview of the three main components of the ICC-MS platform. ICC-MS 
is a versatile approach delivering limited number of candidates with a high potential for functional 
relevance. The competitive binding step is allowing the ranking of binders based on their specificity. 
The endogenous profiling in in-vivo like conditions is increasing the chance of identifying biologically 
relevant interactions. Finally, there is no need for prior knowledge and there is no restriction to 
previously published interactions by the combination with a MS readout. 
The molecular apparatus of a cell being not only controlled by protein-protein interactions but 
also largely by protein-nucleic acid interactions [93], the next step was to adapt ICC-MS to the 
study of proteome-wide binding to RNA. 
  
63 
 
3.2. ICC-MS-derived platform as an RNA-centric approach to study 
proteome-wide binding 
 
The molecular basis of protein-RNA interactions is not completely understood but the role of 
RNA-binding proteins (RBPs) in cells is central from RNA fate to its synthesis and decay [94, 
95]. Innovative technologies are heavily needed to complement our knowledge in that field. 
An approach derived from ICC-MS could fill the gap by offering an increased specificity and 
accuracy compared to more classical protein centric (RIP-chip) and RNA-centric (RNA pull-
downs) approaches. 
The ICC-MS platform has been developed and optimized to be used with an antibody 
immunoprecipitating a protein of interest together with its interacting partners. In the first 
chapter, the high specificity of ICC-MS could be demonstrated in three different cellular 
models. In this second chapter, it was tested whether a similar platform can be applied as a 
RNA-centric approach to screen in an unbiased fashion for protein-RNA interactions (Figure 
3.27). The biggest challenge of such an Oligo-Competitive Capture Mass Spectrometry (OCC-
MS) approach is to deal with an even higher amount of background proteins due to the fact that 
RNA molecules are large in size and negatively charged (phosphate groups). Thus conditions 
ensuring capture to an extent that allows detection of interacting partners while efficiently 
filtering out non-specific binders needed to be established and validated. For a proof-of-
principle study two well characterized RNA-protein complexes were chosen: the Iron 
Regulatory Element-Aconitase complex and the Androgen Receptor-Hu-antigen R complex. 
After validating the technical feasibility, the approach was applied to dissect the mode of action 
of survival of motor neuron (SMN) splicing modifiers. 
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Figure 3.27: Schematic outline of the OCC-MS experimental procedure to identify protein-RNA 
interactions. Protein extracts are first pre-incubated with increasing concentrations of the free form of 
specific oligonucleotide sequence. Extracts are then individually loaded on agarose beads with the same 
oligonucleotide sequence immobilized. The unbound fractions are discarded and beads are washed 
several times. Bound proteins are eluted from the beads and digested with trypsin. Extracted peptides 
are analyzed by LC-MS/MS on an Orbitrap mass spectrometer. Relative protein abundances are 
translated from peptide extracted ion chromatograms (EICs) and finally subjected to a statistical 
analysis to derive concentration-dependent signal decrease of the specific interactors. 
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3.2.1 Technical feasibility study using the Iron Regulatory Element-Aconitase 
complex 
The protein Aconitase is a bifunctional protein catalyzing the isocitrate/citrate interconversion 
but acting also as an RBP binding to Iron Regulatory Element (IRE) that are part of a family 
of non-coding mRNA sequences regulating iron homeostasis [96, 97]. 
To perform affinity purifications, 3’ biotinylated IRE sequences were selected and used as baits 
on streptavidin magnetic beads in human fibroblasts. 
The ultimate goal of such a RNA centric strategy is to better understand the role of specific 
RBPs in mRNA transcription and processing rather in the nucleus than in mRNA fate in the 
cytoplasm (i.e., subcellular localization, metabolism or translation). Thus, it was important to 
evaluate from the beginning whether nuclear fractions of cells could serve as starting material. 
Thus, a procedure allowing a proper separation of nuclear from cytosolic fractions while 
ensuring proteins solubilization, native conformation and protein interactions was required. 
Human fibroblasts subcellular fractionation was performed by re-suspending cell pellets in a 
hypotonic HEPES buffer. After mechanical disruption and centrifugation, nuclear pellets were 
re-suspended in 0.5% NP40 lysis buffer containing protease and RNase inhibitors. To confirm 
the efficiency of fractionation, aliquots of cytosolic and nuclear fractions were loaded on SDS-
PAGE and transferred for immunoblotting against nuclear and cytoplasmic control proteins 
(Figure 3.28). The nuclear proteins Lamin B and Histone H2B were exclusively detected in the 
nuclear fractions whereas the cytosolic 14-3-3 αß protein was detected in the cytosolic fraction. 
Thus, this protocol is efficiently extracting nuclei while being compatible with the approach 
having a low concentration of non-denaturating detergent. 
The amount of biotinylated IRE RNA immobilized on streptavidin magnetic beads was the 
next parameter to be explored. 
50 µl of nucleic-acid compatible streptavidin magnetic beads (supplied at 10 mg/ml) were 
mixed with 0, 50, 100, 250 or 500 pmol of biotinylated IRE for 30 minutes and incubated then 
with 150 µg of human fibroblast nuclear extracts for 1 hour. After a few washing steps, IRE 
binders were eluted, separated by SDS-PAGE and transferred for Aconitase immunoblotting 
(Figure 3.29). 
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With an amount of 50 pmol of biotinylated IRE RNA immobilized on 50 µl of streptavidin 
magnetic beads, Aconitase was almost completely captured from the human fibroblast nuclear 
extracts. Only a weak signal was remaining in the unbound fraction. Based on these findings 
the amount of 100 pmol was selected to increase the chance in future experiments to identify 
lower abundant proteins as well. Higher amounts such as 250 and 500 pmol turned out to be 
slightly suboptimal probably due to steric hindrance. 
 
 
Figure 3.28: Nuclear extracts quality check from human fibroblasts. 10 µg of human fibroblasts 
nuclear (NF) and cytosolic extracts (CF) were separated by SDS-PAGE, transferred on PVDF 
membrane and probed for Histone H2B (nuclear protein), Lamin B (nuclear protein) and 14-3-3 αß 
(cytosolic protein). 
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Figure 3.29: Capture of Aconitase by increasing amounts of IRE RNA immobilized on beads. IRE 
pull-downs were performed in human fibroblast nuclear extracts (150 µg of total protein) with 0, 50, 
100, 250 or 500 pmol of biotinylated IRE (5'- UCCUGCUUCAACAGUGCUUGGACGGAAC -3') 
immobilized on streptavidin magnetic beads. Nuclear extracts (10 µg), unbound (10 µg) and bound 
fractions (Bound: 20 µl of elution, Bound +: 30 µl of elution; from a total elution volume of 100 µl) 
from IRE pull-down experiments were probed for Aconitase by immunoblot using anti-Aconitase 
EPR7225. 
 
A prerequisite to benefit from the theoretical specificity of the OCC-MS approach was to 
demonstrate the feasibility to combine an efficient capture of RBP with a competitive binding 
between immobilized and free RNAs. This was assessed by pre-incubating human fibroblast 
nuclear extracts (150 µg of total protein) with 0, 50, 100, 500 and 1000 pmol of free IRE RNA 
prior to IRE pull-down (Figure 3.30). A reduced signal of the captured Aconitase protein was 
detected upon applying 50 pmol of free IRE competitor and the largest drop was observed by 
adding 500 pmol. Finally pre-incubation of the cellular extract with 1000 pmol led to complete 
loss of Aconitase signal in the bound fraction. Thus, it is technical feasible to introduce a 
binding competition and ultimately to benefit from this strategy to identify specific binders. 
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Figure 3.30: Aconitase immunoblot from IRE RNA-competitive pull-downs in cellular nuclear 
extracts. 150 µg of human fibroblast nuclear extracts were pre-incubated with 0, 50, 100, 500 and 1000 
pmol of free IRE RNA sequences before affinity purification using biotinylated IRE immobilized on 
streptavidin magnetic beads (100 pmol on 50 ul of beads). Nuclear extract (10 µg) and bound fractions 
(30 µl from 100 µl total elution volume) were probed for Aconitase immunoblot using a secondary 
antibody coupled to HRP and chemiluminescence as a mode of detection. Lamin added as a non-RBPs 
control. 
3.2.2 Technical feasibility study using Androgen Receptor-Hu-antigen R complex 
To further confirm, the technical feasibility of an OCC-MS approach to profile RNA-proteins 
interactions, a second model was explored. The Hu-antigen R protein (HuR), a well described 
RBP part of the Elav/Hu family which has been shown to bind avidly to UC-rich region within 
the 3’-Untranslated Region (UTR) of the Androgen Receptor (AR) messenger RNA (mRNA) 
[98]. Thus 3’ biotinylated AR RNA were selected for immobilization on streptavidin magnetic 
beads (100 pmol on 50 µl of beads). 
HuR was efficiently affinity purified from human fibroblast nuclear extracts (140 µg) although 
some signal could still be detected in the unbound fraction (Figure 3.29). Subsequently, nuclear 
extracts were pre-incubated with 0, 100, 200 and 300 pmol of free AR RNA prior to be 
individually loaded on immobilized biotinylated AR RNA. Notably, the amount of 300 pmol 
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of free AR RNA was not enough for complete loss of the HuR in the bound fraction signal. 
However, a concentration-dependent signal decrease was observed, successfully assigning 
HuR as an AR RNA binder (Figure 3.31). 
At this stage, it was important to verify that a signal decrease upon increasing concentrations 
of free AR RNA was not observed for a non-specific binder. The heterogeneous nuclear 
ribonucleoprotein A1 (ROA1), a well-characterized RBP involved in many aspects of RNA 
processing [99] and being highly and ubiquitously expressed, was selected for these analysis. 
ROA1 was detected in the AR RNA bound fraction in absence of competing free AR RNA and 
could have been identified as a potential AR binder in the context of a binary comparison. 
However, incubation with increasing concentrations of free AR RNA showed no impact on its 
capture, which is a characteristic behavior of a non-specific binder in such an experiment. 
It is important in this second chapter to clearly differentiate “non-specific binders” from 
proteins binding to RNA substrates at “non-specific sites”. The focus of this thesis is on “non-
specific binders”, i.e. highly abundant or ‘sticky’ proteins interacting with a matrix or a 
chemical backbone without any relation to biological activity. The latter also often named as 
“background” does not include the numerous proteins which are having important biological 
roles by interacting with RNAs irrespectively of specific sequences or structure signature. 
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Figure 3.31: AR RNA-competitive pull-downs in cellular nuclear extracts. 140 µg of human 
fibroblast nuclear extracts were pre-incubated with 0, 100, 200 and 300 pmol of free AR RNA (5´- 
CUGGGCUUUUUUUUUCUCUUUCUCUCCUUUCUUUUUCUUCUUCCCUCCCUA -3´) prior to 
affinity purification using biotinylated AR RNA immobilized on streptavidin magnetic beads. Nuclear 
extract (10 µg) Unbound (20 µg) Bound fractions (20 µl from 100 µl total elution volume) probed for 
HuR and ROA1. 
 
Altogether, these results confirmed the technical feasibility of OCC-MS to profile RNA-protein 
interactions. The next step being to test the combination to MS as a readout which is offering 
then the possibility to screen in an unbiased fashion the whole proteome. 
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3.2.3 Application to decipher survival of motor neuron (SMN) splicing modifiers 
mode of action 
In eukaryotic organisms, RNA splicing is a complex post-transcriptional RNA processing 
mechanism based on removal of introns from precursor messenger mRNA (pre-mRNA) 
followed by exon ligation ultimately leading to mature mRNA [100]. A single gene can then 
code for different protein isoforms via pre-mRNA alternative splicing [101]. This step is 
regulated by the spliceosome, a large ribonucleoprotein complex [102], composed of multiple 
proteins (trans-acting factors) recognizing exonic or intronic sequence-specific sites (cis-acting 
elements) which are acting as splicing enhancers or silencers. 
Mis-splicing events due to hereditary or somatic mutations can have dramatic pathological 
consequences [103]. One example is spinal muscular atrophy (SMA), the leading genetic cause 
of infant mortality (1 in 10’000 births) associated with progressive degeneration of spinal 
motoneurons [104, 105] due to loss of survival motor neuron (SMN) full-length protein. SMN 
protein is encoded by SMN1 and SMN2 genes having nine exons. SMN2 exon 7 is often skipped 
due to a C-to-T transition at position 6 which was suggested to either disrupt an Exonic Splicing 
Enhancer (ESE) motif or to create an exonic splicing silencer (ESS) [106, 107]. This is leading 
to mRNA translation into a truncated and unstable protein. In SMA patients, SMN1 is mutated 
or deleted and the level of SMN2 mis-splicing is directly related to the severity of the disease 
(Figure 3.32). SMA type 1, accounting for almost 60% of all cases, is the most severe form of 
the disease with life expectancies of less than eighteen months. Therapeutic strategies targeting 
SMN2 alternative splicing are highly attractive although targeting splicing machinery can be 
associated with weak specificity. 
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Figure 3.32: Representation of SMN1 and SMN2 genes and protein product in SMA patients. In 
SMA, SMN1 is mutated or deleted. SMN2 a nearly identical copy of SMN1 is differing by a C-to-T 
transition at position 6 of exon 7 (probably in an ESE region) leading to frequent exon skipping. Mis-
spliced mRNAs are translated into truncated and unstable proteins. The lower the level of functional 
SMN protein is, the more critical the symptoms of the disease are. In light blue, how SMN2 splicing 
modifiers would act to ensure proper production of SMN functional protein. 
 
In this context, Roche Innovation Center Basel developed the SMN-C class of molecules which 
are promising SMN2 splicing modifiers [108] showing high selectivity towards SMN2 via a 
unique mode of action [109]. SMN-C compounds were shown to interact with two distinct 
sites, the exonic splicing enhancer 2 (ESE2) region of exon 7 and the 5’splice site (ss). Both 
sites were revealed to be important for the specific activity of SMN-C in promoting exon 7 
inclusion in SMN2 transcripts. 
To study in further depth SMN-C mode of action, an OCC-MS approach was applied to identify 
trans-acting splicing factors associated with the ESE2 motif in SMN2 exon7 (Figure 3.33 A) 
followed by an exploration how SMN-C compounds influence their binding properties (Figure 
3.33 B). 
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Figure 3.33: Schematic outline of OCC-MS approach applied for SMN-C mode of action 
deciphering. Nuclear extracts from SMA type 1 patient fibroblasts were first pre-incubated with 
increasing concentrations of free SMN2 ESE 2 (A) or free SMN-C compound (B). Extracts were then 
individually affinity purified on biotinylated SMN2 ESE2 immobilized on streptavidin magnetic beads. 
After washing the beads several times, bound proteins were eluted and further processed for protein 
identification by LC-MS/MS as described in section 3.1. Similar statistical analysis to the one described 
in section 3.1 was applied to derive (A) concentration-dependent signal decrease of SMN2 ESE2 
specific interactors or (B) SMN2 ESE2 interactors displaced by SMN-C compound. SMN2 ESE2 
sequence: 5’ AAA AAG AAG GAA GG 3’. 
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3.2.2.1. Identification of trans-acting splicing factors associated with ESE2 motif in SMN2 
exon7 
To identify SMN2 ESE2-interacting proteins, SMN2 ESE2 pull-downs (100 pmol biotinylated 
SMN2 ESE2 immobilized on 50 µl streptavidin magnetic beads) were performed in 170 µg of 
SMA type 1 fibroblast nuclear extracts previously incubated with increasing quantities of free 
SMN2 ESE2 (0, 50, 100, 500 and 1000 pmol in 70 µl total volume) in triplicates. 3’ end 
biotinylated SMN2 ESE2 sequences were provided by Manaswini Sivaramakrishnan and Sonja 
Meier from the lab of Friedrich Metzger at Roche Innovation Center Basel. The fifteen bound 
fractions (five concentrations of free SMN2 ESE2 in triplicates) were randomized, separated 
on SDS-PAGE and cut into five gel slices (Figure 3.34). The resulting 75 samples were in-gel 
digested and further processed for protein identification by LC-MS/MS. In total, 1413 proteins 
were identified and quantified in the bound fraction. A dose-response statistical analysis was 
then applied on the MS output by Balazs Banfai, Gonzalo Duran-Pacheco and Jens Lamerz 
[109] to check if specific binders can be efficiently extracted from such a high number of 
background proteins. Among the 1413 proteins identified and quantified, 42 proteins only were 
significantly displaced upon increasing free SMN2 ESE2 concentrations (Adj-p value < 5%, 
identified with at least two unique peptides and signal reduction > 50%) (Table 3.6). 
 
Figure 3.34: SDS-PAGE separation from ESE2 bound fractions in SMA type 1 patient fibroblasts 
nuclear extracts pre-incubated with free ESE2. ESE2-interacting proteins were extracted (100 pmol 
of biotinylated ESE2 on 50 µl of magnetic beads) from SMA type 1 patient fibroblasts nuclear extracts 
(170 µg total protein) pre-incubated with 0, 50, 100, 500 and 1000 pmol of free SMN2 ESE2 sequences. 
Bound fractions (10 µ1 from 100 µl elution volume) were separated by SDS-PAGE migrated half its 
length and proteins were stained with Coomassie blue. Five bands (from 10 to > 200 kDa) were cut and 
in-gel trypsin digested for protein identification by LC-MS/MS. 
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SwissProt entry pAdj Signal reduction Unique peptides 
SRSF5_HUMAN 0.000177692 92% 3 
TREX1_HUMAN 0.000189166 94% 4 
SRSF1_HUMAN 0.000190289 86% 15 
NUD16_HUMAN 0.000190667 84% 8 
RU1C_HUMAN 0.000191046 83% 3 
SNRPA_HUMAN 0.000191426 85% 15 
RSMB_HUMAN 0.000192192 77% 8 
TRA2B_HUMAN 0.000193742 75% 7 
GRSF1_HUMAN 0.000218898 97% 18 
NUCL_HUMAN 0.000219397 98% 38 
ACOT9_HUMAN 0.0002199 85% 5 
PABP2_HUMAN;EPAB2_HUMAN 0.000220404 97% 6 
HNRH2_HUMAN 0.000220911 82% 18 
HNRPF_HUMAN 0.000221931 87% 23 
STRAP_HUMAN 0.000222961 96% 14 
DAZP1_HUMAN 0.000223479 93% 5 
HNRH1_HUMAN 0.000224524 72% 23 
CSDE1_HUMAN 0.000225049 94% 3 
LA_HUMAN 0.000225578 95% 5 
PLOD1_HUMAN 0.000226108 64% 3 
CNBP_HUMAN 0.000338367 98% 12 
SSBP_HUMAN 0.000340766 70% 6 
SRSF2_HUMAN;SRSF8_HUMAN 0.000341979 75% 4 
SMD2_HUMAN 0.000345669 80% 9 
SRSF1_HUMAN;SRSF9_HUMAN 0.000346917 75% 3 
SMD3_HUMAN 0.000348174 74% 10 
RBM3_HUMAN 0.00034944 68% 7 
ROA1_HUMAN;RA1L2_HUMAN 0.000384531 65% 31 
SRSF6_HUMAN 0.000407221 84% 3 
TRA2A_HUMAN 0.000408039 79% 2 
SRSF4_HUMAN 0.00040886 93% 2 
PURA_HUMAN 0.00043592 55% 11 
PURB_HUMAN;PURG_HUMAN 0.000437938 73% 14 
CIRBP_HUMAN 0.000871242 67% 7 
RL19_HUMAN 0.001205751 57% 13 
RU17_HUMAN 0.00148403 85% 12 
RUXE_HUMAN 0.00177071 57% 5 
RUXF_HUMAN 0.003313015 61% 4 
SMD1_HUMAN 0.005371784 59% 5 
RTCA_HUMAN 0.013982808 99% 4 
PCBP2_HUMAN;PCBP3_HUMAN 0.014945568 71% 2 
ZCCHV_HUMAN 0.015148165 69% 3 
 
Table 3.6: ESE2-interacting candidates identified after statistical analysis of MS data. pAdj: p 
value adjusted by the Westfall-Young approach; Signal reduction: Signal difference between the highest 
and lowest concentration of free antibody; Unique peptides: number of peptides assigned to a protein 
quantitation group. Ranked by increasing adjusted p-values, then decreasing signal reduction and 
number of peptides. 
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Notably, most of the identified proteins are previously reported as RBPs. To check whether 
some of them are interacting with each other, the 42 ESE2-interacting protein candidates were 
uploaded in the Search Tool for the Retrieval of Interacting proteins database (SRINGdb). 
Actually, it appeared that many of them were previously reported as interacting with each other 
(Figure 3.35) which indicate a probability for some of them to be captured as part of a complex 
rather than as direct binders. 
In the list, many serine-rich (SR) proteins were identified which are indeed known to bind and 
promote exon splicing in regions with ESEs. Many heterogeneous ribonucleoprotein particles 
(hnRNPs) were also found in the list of ESE2-interacting proteins although those proteins are 
more often associated with blocking of exon splicing in regions with ESSs via RNA-binding 
domains and splicing inhibitory domains (e.g. glycine-rich motifs) [110]. 
 
 
Figure 3.35: PPI network of ESE2-interacting candidates. The 42 protein candidates identified as 
ESE2-interacting proteins were loaded in the STRING DB (https://string-db.org/) using the highest 
confidence (0.900) in term of interaction score from curated databases (blue lines) as well as 
experimentally determined (pink lines). 
The validity of the approach is confirmed by the presence of Tra2-ß1 in the list of ESE2-
interacting protein candidates (pAdj 0.000193742, Figure 3.36). Indeed, Tra2-ß1 is a well 
described ESE2 trans-acting factor acting as an important actor of exon7 inclusion. The RNA 
recognition motif (RRM) of Tra2-ß1 was shown to recognize specifically a 5’ AGAAA 3’ 
motif within ESE2 [111] and this interaction is proposed in current models to lead to the 
recruitment of two other splicing factors SRSF9 and RBMX [112, 113]. Those proteins, known 
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to play a major role in SMN2 exon7 inclusion, in contrary to Tra2- ß1 were not identified as 
ESE2-interacting partners (Figure 3.36). It is known that RBMX is not requiring a specific 
motif to bind SMN exon 7 RNA [113] and that SRSF9 is a weak affinity RNA binder [112]. 
Those proteins are also described to interact directly with Tra2-ß1. The fact that none were 
identified as co-eluting with Tra2-ß1 could indicate either a weak/transient affinity or that the 
complex formed by ESE2, Tra2-ß1, SRSF9 and RBMX might be active only during pre-mRNA 
processing. 
  
Figure 3.36: Tra2-ß1 identified as ESE2-interacting candidate. Displacement profiles of Tra2-ß1, 
SRSF9 and RBMX obtained from ESE2 RNA-competitive pull-downs in human SMA type 1 nuclear 
extracts. 170 µg of human fibroblast nuclear extracts were pre-incubated with 0, 50, 100, 500 and 1000 
pmol of free ESE2 prior to pull-down with biotinylated ESE2 immobilized on streptavidin magnetic 
beads. Proteins from bound fractions were identified by LC-MS/MS and MS signals are subjected to a 
statistical analysis to derive concentration-dependent signal decrease of specific interactors. 
It should be noted that a protein group formed by SRSF1 and SRSF9 was found in the list of 
potential ESE2-interacting candidates (Table 3.6) but the displacement observed was probably 
driven by SRSF1 peptides as observed in Figure 3.37. 
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Figure 3.37: SRSF1 but not SRSF9 is identified as ESE2-interacting candidate. Displacement 
profiles of SRSF1, SRSF9 and the protein group SRSF1-SRSF9 obtained from ESE2 RNA-competitive 
pull-downs in human SMA type 1 nuclear extracts. 170 µg of human fibroblast nuclear extracts were 
pre-incubated with 0, 50, 100, 500 and 1000 pmol of free ESE2 prior to pull-down with biotinylated 
ESE2 immobilized on streptavidin magnetic beads. Proteins from bound fractions were identified by 
LC-MS/MS and MS signals were subjected to a statistical analysis to derive concentration-dependent 
signal decrease of specific interactors. 
 
Altogether, these findings suggest a high relevance of combining competitive binding to RNA 
pull-downs in order to identify specific RBPs. However, additional factors than SR and SR-
like proteins such as hnRNP proteins were identified and are probably involved in exon 
inclusion through direct or indirect interactions. 
3.2.2.2. SMN-C compound effect on trans-acting splicing factors associated with ESE2 
The OCC-MS approach revealed a protein complex associated with ESE2 motif in SMN2 
exon7. The impact of SMN-C splicing modifier on that complex was then explored (Figure 
3.33 B). Studying the effect of SMN-C splicing modifier directly on ESE2 trans-acting splicing 
factors would indeed offer an opportunity to get a deeper understanding of its mode of action. 
Two SMN-C compound derivatives were synthesized by Hasane Ratni (Roche Innovation 
Center Basel) to assess their effect on ESE2 interacting partners (Figure 3.38). Both compounds 
were tested by Hasane Ratni for their ability to modify SMN2 splicing in a cellular assay using 
type 1 patient fibroblast. One compound was having an EC50 (concentration of drug that gives 
half-maximal response) of 43 nM in modifying SMN2 splicing (Figure 3.38, “Active SMN-
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C”). The additional carbonyl introduced at one extremity of the other compound led to a drop 
in its potency (EC50 > 1 µM, Figure 3.38, “Inactive SMN-C”) [109]. 
 
 
Figure 3.38: Chemical structures of SMN-C active and inactive derivatives. Active SMN-C and 
inactive SMN-C were synthesized and tested for their potency in modifying SMN2 splicing in a cellular 
assay using type 1 patient fibroblasts by Hasane Ratni. The carbonyl group introduced at one extremity 
of the SMN-C inactive analog molecule is resulting in EC50 shift from 43 nM to above 1 µM (data not 
shown). 
To assess the effect of both compounds to ESE2 interactome, affinity purifications were 
performed in human SMA type 1 fibroblasts nuclear (150 µg total proteins). Prior to the capture 
with 100 pmol of biotinylated ESE2 immobilized on streptavidin magnetic beads, nuclear 
extracts were pre-incubated with increasing concentrations (0, 0.5, 1, 5 and 10 µM in 
triplicates) of either active or inactive SMN-C derivatives. Thirty bound fractions (five 
concentrations of free SMNC active or inactive in triplicates) were randomized, separated on 
SDS-PAGE and cut into five gel slices (Figure 3.39). 
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Figure 3.39: SDS-PAGE separation from ESE2 bound fractions in SMA type 1 patient fibroblasts 
nuclear extracts after competition with free SMN-C compounds. ESE2-interacting proteins were 
extracted (100 pmol of biotinylated ESE2 on 50 µl of magnetic beads) from SMA type 1 patient 
fibroblasts nuclear extracts (150 µg total protein) pre-incubated with 0, 0.5, 1, 5 and 10 µM of free 
SMN-C active or inactive compounds in triplicates. Bound fractions (10 µl from 100 µl elution) were 
separated by SDS-PAGE migrated half its length and proteins were stained with colloidal blue. Five 
bands (from 10 to > 200 kDa) were cut and in-gel trypsin digested for further protein identification by 
LC-MS/MS. 
The resulting 150 samples were in-gel digested and further processed for protein identification 
by LC-MS/MS. In total, 850 proteins were identified and quantified in ESE2 RNA pull-down 
both in presence of active SMN-C or of its inactive analog. Notably, none of those proteins 
were found to be significantly displaced by increasing concentrations of SMN-C inactive 
analog (Adj-p value < 5% and identified with at least two unique peptides) after extracting 
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dose-response relationships. On the other hand, increasing concentrations of active SMN-C led 
to the specific displacement of ten proteins from ESE2 sequence (Adj-p value < 5% and unique 
peptides > 1; Table 3.7). Based on STRINGdb (Figure 3.40), four of these proteins are 
described to be part of a complex: U1 snRNP proteins A and 70, FUS and more interestingly 
SMN2 exon 7 inclusion promoter RBMX. 
SwissProt entry Gene name pAdj Signal reduction Unique peptides 
NUCL_HUMAN NCL 0.000196516 36% 45 
FUS_HUMAN FUS, TLS 0.000206215 43% 3 
SNRPA_HUMAN SNRPA 0.000206658 38% 5 
RBMX; 
RBMXL1-2-3_HUMAN 
HNRPG 0.000207551 29% 15 
RU17_HUMAN SNRNP70 0.00033 63% 3 
STRAP_HUMAN STRAP 0.000384531 53% 11 
CSDE1_HUMAN CSDE1 0.0003861 49% 11 
DAZP1_HUMAN DAZAP1 0.000387683 49% 2 
RBM45_HUMAN RBM45 0.000388479 52% 3 
EWS_HUMAN EWSR1 0.000394144 45% 2 
Table 3.7: SMN-C interacting candidates identified after ESE2 pull-down. pAdj: p value adjusted 
by the Westfall-Young approach; Signal reduction: Signal difference between the highest and lowest 
concentration of free antibody; Unique peptides: number of peptides assigned to a protein quantitation 
group. Ranked by increasing adjusted p-values, then decreasing signal reduction and number of 
peptides. 
 
Figure 3.40: PPI network of SMN-C-interacting proteins on ESE2. The ten protein candidates 
identified as SMN-C-interacting proteins after affinity enrichment with the SMN2 ESE2 RNA sequence 
as bait were loaded in the STRING DB using the highest confidence (0.900) in term of interaction score 
from curated databases (blue lines) as well as experimentally determined (pink lines). 
82 
 
The identification of RBMX, and not Tra2-ß1 or SRSF9, as specific interactor of SMN-C 
compound raised particular interest (Figure 3.41 and 3.42). This suggests a direct interaction 
of SMN-C at the RNA-interaction site of RBMX. However, it should be noted that although 
highly statistically relevant, the level of displacement upon increasing concentration of SMN-
C was only of 29% (Figure 3.41). The observed signal reductions were actually below 60 % 
for all candidates (Table 3.7) indicating that the amount of free compound added prior to the 
ESE2 affinity purification was probably a limiting factor. Nevertheless direct binding of SMN-
C active compound to RBMX (and not to Tra2-ß1) and its subsequent displacement from ESE2 
could be confirmed via orthogonal methods, i.e. Surface Plasmon Resonance (SPR)-binding 
analyses and Nuclear Magnetic Resonance (NMR) chemical-shifts [109]. 
 
Figure 3.41: Displacement of RBMX from SMN2 exon 7 ESE2 by SMN-C splicing modifier. 
Protein abundance (log2) of RBMX after affinity enrichment with the SMN2 ESE2 RNA sequence as 
bait, in the presence of increasing concentrations of (A) Active SMN-C or (B) Inactive SMN-C ligand. 
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Figure 3.42: Affinity enrichment of Tra2-ß1 and SRSF9. Protein abundance (log2) of Tra2-ß1 (A) 
and SRSF9 (B) after affinity enrichment with the SMN2 ESE2 RNA sequence as bait, in the presence 
of increasing concentrations of (A) Active SMN-C or (B) Inactive SMN-C ligand. 
These results indicate that the exquisite specificity of SMN-C as positive regulator of SMN2 
exon 7 inclusion might be explained by its direct interaction to multiple trans-acting splicing 
factors. SMN-C might stabilize RBMX and U1 snRNP interaction to ESE2 or on contrary 
reorganize their position or even lead to recruitment from other proteins. 
To summarize the results of this section, OCC-MS successfully dissected ESE2 interactome 
and contributed to a better understanding of SMN2 splicing modifier mode of action. It is 
validating OCC-MS as a relevant approach to screen RNA-protein interactions. The specificity 
given by the competitive capture is allowing to deal with the high background of non-specific 
binders. Moreover, the conditions in which the capture is performed is allowing the capture of 
protein networks.  
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3.3. ICC-MS-derived platform to study protein interactions to single-
stranded antisense oligonucleotides (ASOs) 
 
Antisense oligonucleotides (ASOs) are synthetic polymers, usually between 15 to 20 
nucleotides and their 3’-5’ sequence is complementary to the sense sequence of a specific RNA 
transcript according to Watson-Crick base pairing. 
Drug discovery approaches based on RNA targeting using ASOs leading to an altered synthesis 
of a particular protein, are highly promising. Antisense drugs bind (hybridize) to a target RNA 
forming a duplex further preventing proper production of disease-causing proteins via different 
approaches. The most widely used method is the activation of the endonuclease Ribonuclease 
H (RNase H) [114], but additional mechanisms having an impact on RNA splicing and 
translation machineries can be considered as well [115, 116]. 
The potential of antisense drugs has been illustrated in 2016 by the approval of Nusinersen 
which has been developed to treat SMA pathology [117]. 
To reach market approval, this approach has been evolving since the last three decades. 
Multiple ASO modifications led to improvement in nuclease resistance, increased half-life, 
higher target affinity, better distribution and cellular uptake [118]. However, there are still 
limitations due to severe side effects as toxic findings especially in the liver and the kidney. 
Interactions of ASOs with proteins have been shown to influence their potency and cellular 
localization [119]. However, the overall impact of protein interactions on the efficacy, 
pharmacokinetics and safety of therapeutic ASOs is still poorly understood. 
Profiling ASOs-protein interactions might lead to a better understanding of the role of ASO 
binding proteins and ultimately might help in designing safer ASOs. As for RNAs, ASOs are 
by nature highly charged and large, therefore a strategy to filter out non-specific binders could 
represent an interesting approach to identify relevant interacting proteins. Mapping ASOs 
protein interactome is surely even more challenging as many of them are having a 
phosphorothioate (PS) backbone (Figure 3.43) which is increasing their half-lives and cellular 
uptake [120] but which binds even more avidly to proteins than a phosphodiester. In addition, 
some ASOs are locked nucleic acid (LNA, Figure 3.43) with constrained ethyls increasing 
target affinity but which are highly hydrophobic 2’ modification binding also many more 
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proteins. Some ASOs are conjugated to N-acetylgalactosamine (GalNAc, Figure 3.43) moieties 
which is allowing a liver-targeted uptake via the binding to the asialoglycoprotein receptor 
(ASGPR) expressed specifically and at a high copy number on the surface of hepatocytes (e.g. 
for diseases such as hepatitis B) [121-123]. 
 
 
Figure 3.43: Common ASOs chemical modifications. ASOs are single-stranded sequences of DNA 
with a phosphate backbone and sugar rings. In ASOs backbone, non-bridging phosphodiester oxygen 
is often replaced by a sulfur (phosphorothioate) to increase stability toward nucleases. Locked nucleic 
acids (LNAs) are having a 2’, 4’-methylene linkage which is locking the ribose in a favorable 
conformation for interacting with RNA target. Coupling ASOs to N-acetylgalactosamine (GalNAc, 
usually a tricluster), an amino sugar derivative of galactose, is often used when a mediated delivery to 
hepatocytes which abundantly express its receptor (asialoglycoprotein receptor, ASGR) is required. 
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The overall technical feasibility was first assessed in mouse tissue extracts (liver and kidney). 
Then the relation between protein binding profiles and ASO safety assessment was explored in 
vitro in cellular models designed to mimic in vivo nephrotoxicity (human renal proximal tubule 
epithelial cells, PTECs) and hepatotoxicity (mouse 3T3 fibroblast cells). 
3.3.1 Phosphorothioated ASO interactome in mouse liver and kidney tissue 
extracts 
To evaluate whether an OCC-MS approach is suitable to decipher the interactome of large and 
negatively charged ASOs, an assessment in tissue extracts from organs that are typical targets 
of toxicity (i.e. liver and kidney) have been performed. 
The tested ASO (ASO-A) consisted of a LNA gapmer (chemically modified wings and a DNA 
gap in-between), arbitrarily chosen from a library available at Roche Innovation Center Basel 
(Table 3.8). Three nucleotides on each end were LNA modified and the backbone was fully 
phosphorothioated. A 5’ biotinylated version was provided by Erich Koller (Roche Innovation 
Center Basel) and Susanne Kammler (Roche Innovation Center Copenhagen) for 
immobilization on streptavidin magnetic beads. A hexa-ethylene glycol (HEG) spacer arm was 
incorporated to minimize steric hindrance between the biotin moiety and the oligonucleotide 
upon attachment to magnetic beads. 
ASO Target Conjugation 3’ Biotinylation Sequence (5’ to 3’) 
ASO-A VEGF none (naked) No TmCTcctcttccttmCAT 
none (naked) Yes 5’-BioHEG-TmCTcctcttccttmCAT 
Table 3.8: ASO-A: sequences and backbone modifications. Single strand oligonucleotide sequence 
is indicated in blue font. Uppercase: Wing segments of nucleotides with LNA sugar modifications. mC: 
5-methylcytidine. Lower case: Gap segment of 2’-deoxynucleotides. Internucleotide linkages are 
phosphorothioated. BioTEG: biotin extended with a 15 atom triethylene glycol spacer arm. 
Livers from C57 BlbcJ mice were mechanically homogenized in a PBS buffer 1% NP40 with 
protease inhibitor. Samples were sonicated and centrifuged at 16’000 g to remove insoluble 
material. After adding RNase inhibitor, 180 µg of protein extract was incubated with different 
quantities of ASO-A (0, 50, 100, 500 and 1000 pmol in 100 µl in triplicates) prior to capture 
with immobilized biotinylated ASO-A. Bound proteins were eluted with SDS sample buffer 
and loaded for a short SDS-PAGE to eliminate SDS that is LC-MS incompatible and would 
have denaturated the trypsin enzyme used for proteins cleavage. Samples were cut as one band, 
in gel-digested and processed for LC-MS/MS analysis. 
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Due to the inherent nature of LNAs, it was expected to identify a high number of proteins in 
the ASO-A bound fraction and indeed 1792 proteins were identified and quantified (1325 with 
at least two peptides). A Principal Component Analysis (PCA) was performed on the 
normalized protein level data to identify the linear combination of observed variables having 
maximum variance. This revealed that increasing the concentration of free ASO-A was the 
main contributor to the observed variability (Figure 3.44 A). Additionally, dose-response 
relationships were extracted and visualized on a scatter plot of signal reduction versus pAdj 
values (Figure 3.44 B). On such a plot, interesting candidates having a high chance to be 
specific binders of ASO-A are located in the upper right corner (low pAdj value and high signal 
reduction). In line with the previous PCA observations, many proteins were covering both 
criteria, i.e. their capture on immobilized ASO-A was significantly affected by free ASO-A in 
a dose-dependent manner. Also it was not possible to set a strict and clear cut-off pAdj value 
to discriminate specific versus non-specific binders. After visual inspection, it appeared that 
roughly 10% of the proteins identified (> 170 proteins) were displaying a convincing 
displacement profile. Those proteins can be either direct interactors of the immobilized ASO-
A or indirect (part of a complex of proteins). Despite the high number of potential ASO-A 
binder candidates, the approach still efficiently filtered out a large proportion of background 
proteins which were not affected by the presence of the competitor. 
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Figure 3.44: PCA and scatter plot (signal reduction versus pAdj values) after applying OCC-MS 
to ASO-A in mouse liver extracts. 1792 protein groups were identified & quantified after applying an 
OCC-MS approach to ASO-A. A linear model was fit using non-monotonic contrasts (Hirotsu 
contrasts). P values from the tests were adjusted for multiple testing by permutations. (A) PCA on the 
normalized protein level data. Blue dots: 0 pmol; purple dots: 50 pmol, orange dots: 100 pmol, green 
dots: 500 pmol, yellow dots: 1000 pmol, of ASO-A in 100 µl (in triplicates). (B) Scatter plot displaying 
the signal reduction (in %) versus the adjusted p value (-log 2 transformed). pAdj: p value adjusted by 
the Westfall-Young approach; Signal reduction: Signal difference between the highest and lowest 
concentration of free ASO-A. In red, the protein with the lowest pAdj value (nucleolin, 
NUCL_MOUSE, 5.4e-05) and in green asialoglycoprotein receptor 1 (ASGR1_MOUSE). Horizontal 
lines at pAdj value 0.1, 0.25 and 0.5 and vertical line at 50% signal reduction. 
The protein with the lowest pAdj value (5.4e-05) was the abundant nucleolar protein nucleolin 
(NUCL, signal reduction of 93%) known to have 4 consensus RNA-binding domains called 
RNA recognition motifs (RRM) [124]. Nucleolin was previously described as a binder of PS-
ASOs and nucleolin-specific aptamer-mediated delivery of ASOs has been evaluated to 
increase the activity of splicing-modulation ASOs in different cancer cells [119, 125]. ASGR1 
has also been identified as a specific binder (with a pAdj value of 0.002648 and a signal 
reduction of 87%, Figure 3.45) which was surprising as ASO-A was not GalNac modified. 
89 
 
Nevertheless, this finding was in agreement with recent published data indicating that even 
unconjugated phosphorothioate containing ASOs may interact with ASGR1 which may play a 
small but significant role in their uptake into hepatocytes and their activity (Tanowitz, 2017). 
 
Figure 3.45: Displacement of NUCL and ASGR1 from ASO-A by ASO-A. Protein abundance (log2) 
of NUCL and ASGR1 after affinity enrichment in mouse liver extracts (180 µg) with ASO-A as bait, 
in the presence of increasing concentrations of free ASO-A (0, 50, 100, 500 and 1000 pmol of free 
ASO-A in 100 µl in triplicates). Proteins from bound fractions were identified by LC-MS/MS and MS 
signals were subjected to a statistical analysis to derive concentration-dependent signal decrease of 
specific interactors. 
Next was investigated whether decreasing the amount of tissue extracts (from 180 µg to 100 
µg) and shifting the concentrations of free ASO-A to a higher range (0, 100, 500, 1000 and 
2000 pmol in 100 µl) improve the discrimination of specific from non-specific binders. In 
addition, kidney extracts were processed in parallel to evaluate the overlap of the findings when 
profiling different tissues. As for the first trial in liver, a high number of proteins were identified 
and quantified in the ASO-A bound fractions (2005 and 2020 proteins respectively in the liver 
and in the kidney extracts). The same observations were made after PCA and after plotting the 
signal reduction versus pAdj values than in the first experiment (Figure 3.46) with a clear 
grouping of the samples based on concentrations of competitor (being the principle axe of 
abundance variation) and an ambiguous cut-off between specific and non-specific binders. 
Thus decreasing the amount of starting material did not have an effect on the number of 
background proteins identified and likewise, a similar percentage (around 10%) of the proteins 
after visual inspection were having a displacement profile. Nucleolin was again among the 10 
first candidates in both extracts (Figure 3.47). ASGR1 specific binding to ASO-A observed in 
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the first trial in liver was confirmed in the second liver experiment but of course not in the 
kidney as ASGR1 is exclusively expressed in liver hepatocytes. 
 
Figure 3.46: PCA and scatter plots (signal reduction versus pAdj values) after applying OCC-MS 
to ASO-A in mouse liver and kidney extracts. 100 µg of mouse liver or kidney protein extracts was 
incubated with different quantities of ASO-A (0, 100, 500, 1000 and 2000 pmol in 100 µl in triplicates) 
prior to captures with immobilized biotinylated ASO-A. Bound proteins were eluted with SDS sample 
buffer and loaded for a short SDS-PAGE to eliminate SDS. Samples were cut as one band, in gel-
digested and processed for LC-MS/MS analysis. 2005 protein groups were identified & quantified in 
liver extracts and 2020 in kidney extracts. A linear model was fit using non-monotonic contrasts 
(Hirotsu contrasts). P values from the tests were adjusted for multiple testing by permutations. (A) PCA 
on the normalized protein level data. Blue: 0 pmol, purple: 100 pmol, orange: 500 pmol, green: 1000 
pmol and yellow: 2000 pmol of ASO-A in 100 µl (in triplicates). (B) Scatter plot displaying the signal 
reduction versus the adjusted p value. pAdj: p value adjusted by the Westfall-Young approach; Signal 
reduction: Signal difference between the highest and lowest concentration of free antibody. Proteins 
identified with only one unique peptide depicted with a smaller circle. 
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Figure 3.47: Displacement of NUCL and ASGR1 from ASO-A by ASO-A in liver and kidney 
extracts. Protein abundance (log2) of NUCL and ASGR1 after affinity enrichment in mouse liver and 
kidney extracts (100 µg) with ASO-A as bait, in the presence of increasing concentrations of free ASO-
A (0, 100, 500, 1000 and 2000 pmol of free ASO-A in 100 µl in triplicates). Proteins from bound 
fractions were identified by LC-MS/MS and MS signals were subjected to a statistical analysis to derive 
concentration-dependent signal decrease of specific interactors. 
To check whether the same proteins were identified as potential ASO-A binders, the overlap 
among the first 200 proteins ranked by increasing pAdj values was explored (Figure 3.48). 
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Figure 3.48: Comparison of the 200 first hits extracted from OCC-MS applied to ASO-A. The list 
of the 200 first hits when ranking with increasing pAdj values in each experiment was compared using 
the tool Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/). 
The overlap between the two liver profiling was around 50% (same extracts but different 
experimental conditions) and close to 40% between liver and kidney (different extracts but 
same experimental conditions). The percentage of similarity was not higher when restricted to 
the first 50 candidates (data not shown). The limited reproducibility observed between the two 
liver experiments was highlighting the importance of the starting conditions (amount of protein 
extracts, level of expression of each individual proteins and range of competitor concentrations) 
and a need for multiple biological replicates to increase the chance to have a manageable 
number of potential candidates (i.e. to identify the “core” proteome). In such an untargeted 
approach compared to the applications previously described in chapter 1 and 2, there were no 
positive controls (i.e. a known interactor) to optimize the experimental conditions. Despite this 
constraint, the approach was further evaluated to compare ASOs with distinct in vitro toxicity 
prediction in cellular models. 
3.3.2 Application to GalNac and naked ASOs with distinct in vitro nephrotoxicity 
prediction 
In vitro screening strategies are critical in drug development to predict risk of toxicity and for 
selection of the most appropriate therapeutic candidate. One of the major safety liability of 
nucleic acid therapeutics is related to ASOs accumulation in kidney tubules and there is a big 
need for in vitro models that would mimic in vivo nephrotoxicity. In 2017 Annie Moisan et al. 
published an in vitro screening strategy using renal proximal tubular epithelial cells (PTEC 
TERT1) to investigate potential risk of nephrotoxicity [126]. In such a screen, ASOs inducing 
a decrease in intracellular ATP, an accumulation of epidermal growth factor (EGF) in PTEC 
supernatants (inhibition of uptake) and morphological changes are highlighted as having a risk 
of safety liability. Interestingly, the team recently reported that GalNac conjugation (ASOs 
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linked at the 5’ terminus to three GalNac molecules via a triantennary linker, triGalNac) was 
having as an effect to mask in vivo nephrotoxicity potential in their assay [45]. Sabine Sewing 
et al. showed that this effect was not due to a poor uptake and lower intracellular content nor 
explained by reduced target gene knockdown. In addition, it has been shown that free triGalNac 
by itself was not masking ASOs cytotoxic effects [45]. 
Thus comparing the protein interactome of GalNac and naked versions might help to better 
understand the protective effect of GalNac conjugation in renal tubular cells in vitro. 
ASOs having known in vivo kidney liabilities but with an inert or attenuated effect of their 
GalNac versions in PTECs were selected, i.e. anti-PCSK9 ASO-B and ASO-C, respectively 
moderately and highly nephrotoxic in rat (Table 3.9) [45]. Biotinylated versions were then 
generated by Adrian Schäublin (Roche Innovation Center Basel) at the 3’ end since 5’ labeling 
would not have been possible for GalNac sequences. 
ASO Target Conjugation 3’ 
Biotinylation 
Sequence (5’ to 3’) 
B PCSK9 none (naked) No TGmCtacaaaacmCmCA 
GalNac No 5’-GN-C6caTGmCtacaaaacmCmCA 
none (naked) Yes TGmCtacaaaacmCmCA-BioTEG-3’ 
GalNac Yes 5’-GN-C6caTGmCtacaaaacmCmCA-
BioTEG-3’ 
C PCSK9 none (naked) No GmCtgtgtgagcttGG 
GalNac No 5’-GN-C6GmCtgtgtgagcttGG 
none (naked) Yes GmCtgtgtgagcttGG-BioTEG-3’ 
GalNac Yes 5’-GN-C6GmCtgtgtgagcttGG-BioTEG-3’ 
Table 3.9: List of PCSK9 ASOs with corresponding sequences and backbone modifications. Single 
strand oligonucleotide sequence is indicated in blue font. Uppercase: Wing segments of nucleotides 
with locked nucleic acid (LNA) sugar modifications. mC: 5-methylcytidine. Lower case: Gap segment 
of 2’-deoxynucleotides. Internucleotide linkages are phosphorothioated. 5'-GN: trivalent N-
acetylgalactosamine (GalNAc) cluster. C6/C6ca: triantennary linker. BioTEG: biotin extended with a 
15 atom triethylene glycol spacer arm. 
For the first experiment, 2E+07 PTEC cells were resupended in 1% NP40 lysis buffer 
containing protease and RNase inhibitors. After centrifugation to remove insoluble material, 
supernatants (90 µg total protein each) were spiked with increasing concentrations (0, 100, 500, 
1000, 2000 pmol in 130 µl total volume) of either naked or GalNac ASO B in triplicates. 
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Extracts were then loaded on their respective biotinylated ASO (50 µl of magnetic beads coated 
with 100 pmol of naked or GalNac biotinylated ASO). 
From the pilot experiment in tissue extracts, a high background and variability was expected 
with no clear cut-off to separate specific from non-specific binders. Thus the whole experiment 
was repeated twice to increase confidence in the findings, resulting in a total of 60 individual 
bound fractions (five concentrations in triplicates, GalNac or Naked, in two biological 
replicates). Fractions were loaded for a short SDS-PAGE to eliminate SDS, were cut as one 
band, in gel-digested and processed for LC-MS/MS analysis. 
Around 1’600 proteins in total have been identified in each bound fractions. At the level of 
protein identification, a similarity around 70% was observed between the replicates as well as 
between naked and GalNac conditions indicating overall a comparable background of proteins 
(data not shown). PCA plots as for the pilot in liver extracts were clearly indicating a strong 
effect on the dataset of increasing concentrations of free ASOs (Figure 3.49 A). Likewise, using 
pAdj values together with the signal reduction to distinguish specific versus non-specific 
binders did not allow identifying a clear cut-off (Figure 3.49 B). 
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Figure 3.49: PCA and scatter plots (signal reduction versus pAdj values) after applying OCC-MS 
to naked and GalNac ASO-B in PTECs extracts. 90 µg of PTEC TERT1 protein extract was 
incubated with different quantities of naked or GalNac ASO B (0, 100, 500, 1000, 2000 pmol in 130 µl 
in triplicates with two biological replicates) prior to captures with immobilized biotinylated ASO B, 
respectively naked or GalNac.  Bound proteins were eluted with SDS sample buffer and loaded for a 
short SDS-PAGE to eliminate SDS. Samples were cut as one band, in gel-digested and processed for 
LC-MS/MS analysis. Around 1’600 protein groups were identified & quantified in each experiments. 
A linear model was fit using non-monotonic contrasts (Hirotsu contrasts). P values from the tests were 
adjusted for multiple testing by permutations. (A) PCA on the normalized protein level data; Blue: 0, 
purple: 100, orange: 500, green; 1000 and yellow: 2000 pmol in 130 µl in triplicates. 
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(B) Scatter plot displaying the signal reduction versus the adjusted p value. pAdj: p value adjusted by 
the Westfall-Young approach; Signal reduction: Signal difference between the highest and lowest 
concentration of free antibody.Young approach; Signal reduction: Signal difference between the highest 
and lowest concentration of free antibody. 
After visual inspection, again at least 10% of the identified proteins were having a displacement 
profile upon increasing concentration of their free ASO either naked or GalNac modified. 
 
 
97 
 
Plotting the adjusted p values between replicates indicated a limited reproducibility (Figure 
3.50). A few proteins (such as nucleolin) were identified repeatedly as specific binders but 
most of the proteins were highlighted as binders in only one replicate. 
 
 
Figure 3.50: Comparison of pAdj values distribution between replicates after OCC-MS applied 
to ASO-B in PTECs extracts (GalNac and naked). Scatter plots displaying the adjusted p value 
(pAdj) among replicates (GalNac and naked). pAdj: p value adjusted by the Westfall-Young approach. 
Lines arbitrarily set at 3.32 (-log2 pAdj 0.1), 2 (-log2 pAdj 0.25) and 1 (-log2 pAdj 0.5). Proteins 
identified with at least two peptides in one replicate. Red dot: nucleolin, NUCL_HUMAN. 
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Keeping as a postulate that the proteins with the lower p-values were having the higher chance 
to be direct binders, a comparison of GalNac and naked datasets using this parameter was 
performed (Figure 3.51). 
 
Figure 3.51: Comparison of pAdj values distribution between GalNac ASO-B and naked ASO-B 
after OCC-MS in PTECs extracts. Scatter plot displaying the adjusted p value (pAdj) GalNac versus 
naked (average of the replicates). pAdj: p value adjusted by the Westfall-Young approach. Lines 
arbitrarily set at 3.32 (-log2 pAdj 0.1), 2 (-log2 pAdj 0.25) and 1 (-log2 pAdj 0.5). Proteins identified 
with at least two peptides in one replicate. Red dot: nucleolin, NUCL_HUMAN. Green dots: hNRPs. 
Quadrant A: lower pAdj values in naked only; Quadrant B: lower pAdj values in GalNac only. 
Many proteins are binding to ASO-B irrespectively of having or not a GalNac moiety attached. 
As an example and similarly to the pilot in liver extracts, the protein nucleolin was found as a 
specific binder in both datasets. The majority of the common proteins identified, were part of 
biological processes such as transcription regulation, mRNA processing and DNA damage. A 
couple of heterogeneous nuclear ribonucleoproteins (hNRPs, in green in Figure 3.51) known 
to interact with each other were identified indicating potentially the capture of a complex of 
proteins. Only a few proteins were showing a more specific binding to the naked (Quadrant A 
99 
 
Figure 3.51, Table 3.10) although many proteins were showing a preference towards the 
GalNac version (Quadrant B Figure 3.51, Table 3.10). This observation was not surprising as 
GalNac molecules are bigger and thus more prone to interact with proteins and could explain 
the masking of in vitro nephrotoxic prediction in PTECs. 
 
Table 3.10: List of proteins having a distinct binding profile to ASO-B GalNac versus ASO-B 
naked. Ranked by increasing ASO-B GalNac pAdj value. Lower pAdj appear in green and higher in 
red. pAdj: p value adjusted by the Westfall-Young approach (average of the replicates). 
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Next OCC-MS was applied to ASO-C in PTECs extracts and proteins from Table 3.10 were 
mapped on the obtained scatter plot of signal reduction versus pAdj values (Figure 3.52 A and 
B). 
 
Figure 3.52: Comparison of pAdj values distribution between GalNac ASO-C and naked ASO-C 
after OCC-MS in PTECs extracts. Scatter plots displaying the adjusted p value (pAdj) of GalNac and 
naked ASO-C. pAdj: p value adjusted by the Westfall-Young approach. Lines arbitrarily set at –log 2 
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of 0.5 (pAdj ~ 70%). Proteins identified with at least two peptides in one replicate. (A) Proteins 
highlighted in dark blue: proteins previously identified with a lower pAdj for naked ASO-B versus 
GalNac ASO-B. (B) Proteins highlighted in dark blue: proteins previously identified with a lower pAdj 
for GalNac ASO-B versus naked ASO-B. Nucleolin (NUCL_HUMAN) in red as a reference. Proteins 
associated to lower pAdj values for both ASO-B and ASO-C either naked (A) or GalNac (B) circled in 
black. 
Again a higher number of binders were observed for the GalNac version. ASO-B “naked 
specific” proteins were either similarly captured by ASO-C naked and GalNac or not captured 
at all. Only Box C/D snoRNA protein 1 (BCD1) and RNA-binding protein 7 (RBM7) were 
having a slightly better displacement profile for naked ASO-C compared to GalNac ASO-C 
(Figure 3.53 A). 
ASO-B “GalNac specific” proteins could be found in all three quadrants, the two most 
confident candidates being band 4.1-like protein 2 (E41L2) and Tuberin (TSC2) (Figure 3.53 
B). 
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Figure 3.53: Displacement profiles of RBM7, BCD1, E41L2 and TSC2. Protein abundance (log2) 
of (A) RBM7, BCD1 (B) E41L2 and TSC2 after affinity enrichment in PTECs (90 μg) with ASO-B or 
ASO-C as bait, in the presence of increasing concentrations of free ASO-B or ASO-C (0, 100, 500, 
1000, 2000 pmol in 130 µl in triplicates). Proteins from bound fractions were identified by LC-MS/MS 
and MS signals were subjected to a statistical analysis to derive concentration-dependent signal 
decrease of specific interactors. 
Taking into account the variability observed in the different trials, none were considered 
confident enough for further follow-up. The masking effect of GalNac ASO seemed to be rather 
driven by the extent of binding (number of binders) than by particular proteins. Consequently, 
naked versions of ASO should always be used for in vitro toxicity prediction. 
In a final attempt to decipher sequence-independent binding of ASOs to cellular proteins which 
might interfere with their biological function and thus may have safety implications, a 
comparison was made between two additional ASOs having again distinct in vitro profiles but 
differing by a much minor modification than GalNac. 
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3.3.3 Application to ASOs with distinct in vitro hepatoxicity profiles 
LNA modifications can improve the potency of ASOs but are often associated with higher risk 
of hepatotoxicity in animals [127]. Potential hepatic liabilities can be predicted in vitro in order 
to de-risk and prioritize ASO candidates. Andreas Dieckmann et al. published recently a new 
cellular model using transfected mouse 3T3 fibroblasts [128]. By delivering ASOs via 
lipotransfection, a clear association between in vivo hepatotoxicity in mouse and apoptosis in 
cells was shown. 
In addition Andreas Dieckmann, Yvonne Burki and Grzegorz Sarek (Roche Innovation Center 
Basel) observed that the insertion of a minor chemical modification into ASO-D hepatotoxic 
oligonucleotide (Table 3.11, and referred as LNA41 in [128]), strongly suppresses toxicity in 
vitro (Figure 3.54). 
ASO Target Sequence (5’ to 3’) 
ASO-D Myd88 CACattccttgctCTG 
Modified ASO-D (MOD ASO-D) Myd88 CACattccttgctCTG 
5’ Biotinylated –ASO-D (BIO ASO-D) Myd88 BioTEG-CACattccttgctCTG 
 
Table 3.11: ASO-D sequences and backbone modifications. Single strand oligonucleotide sequence 
is indicated in blue font. Uppercase: Wing segments of nucleotides with locked nucleic acid (LNA) 
sugar modifications. Lower case: Gap segment of 2’-deoxynucleotides. Internucleotide linkages are all 
phosphorothioated. BioTEG: biotin extended with a 15 atom triethylene glycol spacer arm. MOD : 
modification leading to reduced caspase activity in mouse 3T3 fibroblast cellular assay. 
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Figure 3.54: Modification of toxic ASO-D strongly suppresses in vitro toxicity. Mouse 3T3 
fibroblast cells were transfected using Lipofectamine 2000 with ASO-D and MOD ASO-D, 
respectively. Caspase 3/7 activity was measured 24 hours later. Triplicate transfections were performed; 
the results are shown as a percentage change relative to untreated cells (UTC). Data sere means ± SD. 
Data generated in the lab of Andreas Dieckmann (Roche Innovation Center Basel). 
Our previous attempt to compare protein binding profiles of ASOs with distinct in vitro 
characteristics was particularly complex due to the size of the GalNac modification and the use 
of different hooks for capture (3’ biotinylated GalNac versus 3’ biotinylated naked). 
Here the same biotinylated ASO-D was used for capture and competed by either ASO-D or 
MOD ASO-D. The chemical difference between ASO-D and MOD ASO-D is minor and not 
modifying the oligonucleotide backbone. 
The experiment was performed in Hek293 cell extracts. Briefly, 100 µg total protein were 
spiked with increasing concentrations (0, 5, 25, 100 and 500 pmol in 120 µl total volume) of 
either naked ASO-D or MOD ASO-D prior to being loaded on biotinylated ASO-D (50 µl of 
magnetic beads coated with 100 pmol of biotinylated ASO-D). 
Fractions were loaded for a short SDS-PAGE to eliminate SDS, were cut as one band, in gel-
digested and processed for LC-MS/MS analysis. 
Around 1’300 proteins in total have been identified in each bound fractions (1’000 identified 
with at least two unique peptides). The background of proteins was rather similar with 80% 
overlap (at least two unique peptides, data not shown). Scatter plots comparing pAdj values 
revealed common binders such as nucleolin (Figure 3.55 A) and clearly indicated that many 
more proteins were preferentially binding to ASO-D (Figure 3.55 B) compared to MOD ASO-
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D. The chemical modification led to a “cleaner” protein binding profile which could explain 
the strong suppression of in vitro toxicity. This observation is in accordance with recent 
published data [129] reporting that those protein interactions might be associated with LNA 
mislocalization and cellular stress. 
Among the proteins preferentially binding to ASO-D versus MOD ASO-D (i.e. for which the 
binding was potentially lost upon modification of ASO-D), multiple members from one of the 
most abundant and best characterized DNA binding domain, the Zinc-finger protein family, 
were identified (Figure 3.55 B and 3.56). Although Zinc finger proteins are usually described 
as DNA-binding transcription factors, roles of RNA-binding proteins regulating RNA 
metabolism are reported [130, 131]. The suppression of toxicity observed in vitro with MOD 
ASO-D would need first to be confirmed in vivo before investigating further a potential 
implication of Zinc-finger proteins. 
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Figure 3.55: Comparison of pAdj values distribution between ASO-D and MOD ASO-D after 
applying OCC-MS in Hek293 extracts. Scatter plot displaying the adjusted p value (pAdj) when 
competing with ASO-D versus MOD ASO-D. pAdj: p value adjusted by the Westfall-Young approach. 
Lines arbitrarily set at at 3.32 (-log2 pAdj 0.1), 2 (-log2 pAdj 0.25) and 1 (-log2 pAdj 0.5). Proteins 
identified with at least two unique peptides. Proteins highlighted in dark blue (A) proteins specifically 
binding to both ASO-D and MOD ASO-D (pAdj below 10%) (B) proteins with a lower pAdj for ASO-
D versus MOD ASO-D. Nucleolin (NUCL) highlighted as a reference. In pink: Zinc-finger protein 
family members. 
107 
 
 
Figure 3.56: Displacement profiles of Zinc-finger proteins from ASO-D in Hek293. Protein 
abundance (log2) of ZN767, ZNF24, ZN629, ZCCHV, ZN316 and ZBT21 after affinity enrichment in 
Hek293 (100 µg) with ASO-D as bait, in the presence of increasing concentrations of free ASO-D or 
MOD ASO-D (0, 5, 25, 100, 500 pmol in 120 µl in triplicates). Proteins from bound fractions were 
identified by LC-MS/MS and MS signals were subjected to a statistical analysis to derive concentration-
dependent signal decrease of specific interactors. 
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To summarize, it is not possible to conclude from these results whether ASO safety profiles 
could be partly driven by interaction with specific proteins or by their propensity to bind many 
proteins or a combination of both. Nonetheless, the results show that minor engineering of 
ASOs can lead to a dramatic impact on protein binding properties offering options for more 
favorable safety profiles (i.e. improvement of ASO therapeutic index). 
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4. DISCUSSION 
Understanding the biological function of a protein relies crucially on the identification of its 
interactome in a cellular context. Such sophisticated networks are usually complex to dissect 
and innovative strategies are required to improve the coverage and accuracy of current 
interaction databases. In this thesis, an immuno-competitive capture mass spectrometry (ICC-
MS) approach was implemented and tested in different biological backgrounds. By combining 
competitive capture with MS, ICC-MS is filtering out background proteins to generate highly 
specific protein-protein interaction maps. In each application a limited number of potential 
interactors haven been extracted from the whole proteome and efficiently validated 
functionally. In the first application, LATS kinases were shown to interact with HCV NS5A 
protein and to play a role in viral replication efficiency. Then, FGF2 was revealed as a Gpc2 
interacting candidate having probably an impact on the cell transition from a proliferative to a 
differentiated state. Finally, HtrA1 was identified as a microtubule associated protein in 
alignment with previous observations. The approach has been adapted to capture RNA-protein 
interactions (oligo-competitive capture mass spectrometry or OCC-MS) and contributed to the 
deciphering of SMN splicing modifier mechanism of action by analyzing the effect of the 
presence of the compound on RNA-protein interactions. An attempt to extend OCC-MS to 
extract ASO-protein interactions highlighted some challenges associated to the nature of those 
chemically modified nucleic acid therapeutics. In the following section the observed results are 
critically debated in the context of current available techniques to screen PPIs. 
 
4.1 Affinity purification method selection 
To study endogenous PPIs, many strategies exist (see section 1.4) having all their strengths and 
limitations. A growing interest towards MS-based approaches emerged recently to study 
pathogens’ interactome [132-135]. Among them, AP-MS is one of the most popular screening 
approach in which the target protein together with its interaction partners are isolated by 
affinity binding to an antibody immobilized on a solid support. 
In this thesis, an antibody based co-complex approach has been developed in which proteins 
of interest were captured in their endogenous form. One obvious advantage towards a capture 
through an affinity epitope tag is to ensure isolation of protein complexes close to their 
physiological state and without the need for cloning or tagging. A prerequisite then is to have 
access to an antibody with high affinity (high yield of capture) and specificity (no cross-
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reactivity towards other proteins). Thus to ensure a successful ICC-MS, an extensive validation 
of the capture antibody is required (e.g. validation of NS5A antibody via sequence alignment 
of the epitope, blotting with the capture antibody and IP in the parental cell line which does not 
express the target protein). Although any types of engineering on an endogenous protein is 
associated with a risk to impact protein function, expression, folding or localization (especially 
large protein tags such as GST or GFP), promising alternative such as nanobody based affinity 
systems emerged [92]. In any cases, the outcome of an antibody based profiling exercise will 
always be dependent on the particular epitope of the antibody selected and information will be 
lost at the antibody-binding site. Therefore, using multiple antibodies directed against different 
epitopes on the target protein will likely increase the coverage of the full interactome. 
Low-affinity interactions (such as receptor/ligand) or transient interactions (such as 
enzyme/substrate) might not be detected with ICC-MS, that’s why a combination with 
approaches specifically designed to overcome this limitation would increase mapping 
coverage, e.g. proximity-based labeling methods using either engineered ascorbate peroxidase 
(APEX) or mutated E- coli biotin ligase BirA (BioID) [136], chemical-crosslinking [137] or 
optimized cell surface receptor screens [138]. 
In this thesis, protein-metabolite interactions have not been investigated although there role in 
controlling cellular processes is critical. A recently developed chemoproteomics approach 
named Limited Proteolysis Mass Spectrometry (LiP MS) allow for a systematic and unbiased 
analysis without need for chemical labelling [139]. 
 
4.2 Cellular model selection and protein extraction conditions 
A protein often has multiple interactors associated with different functions in response to 
specific stimulus or cellular state. To ensure that the primary scientific question is addressed 
properly, profiling a protein in an appropriate biological system is essential. Cellular models 
were critically selected for their relevance in each ICC-MS applications reported in this thesis 
(Con1-Huh7 cells, d21 NSC, hfRPE, SMA type 1 fibroblasts and PTECs). It is also crucial that 
the bait protein is reasonably expressed in the cellular model selected which may require to 
optimize the amount of cells utilized as well as the number of cell passages. 
Every steps of the ICC-MS protocol will be influencing the generated list of interacting partners 
(protein amount, salts concentration, detergents, number of washes, incubation time, etc.). Cell 
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lysis should be performed in conditions ensuring protein solubilization but without disruption 
of protein complexes. In this thesis a low concentration of non-denaturating detergent has been 
shown to be appropriate (0.5-1% NP40). 
The majority of the experiments described in this thesis were performed in whole cell lysate. 
Whole extracts have the advantage to potentially yield more target protein and protein 
extraction protocol is faster and milder to preserve native interactions. Many proteins have 
multiple subcellular localizations which means that a whole extract will be then composed of 
a mix of proteins from different subcellular compartments associated to distinct protein 
complexes. For certain applications it can make sense to include a subcellular fractionation 
step depending on the scientific question, e.g. in nuclear extracts to study SMN splicing 
modifier mode of action (MoA). Profiling of subcellular compartments could be a strategy to 
extract functionally relevant ASO-binders as discussed in 4.5. 
 
4.3 Competitive binding strategy and statistical model 
ICC-MS markedly increases the specificity of classical IP by introducing a pre-competition 
step between free and capturing antibody followed by statistical analysis of the quantified MS 
signals. The ability of a free form of an antibody to prevent target capture by an immobilized 
version of the same antibody was demonstrated first using an antibody against HCV NS5A 
protein. The extent of displacement being observed in a dose-dependent manner (Figure 3.4), 
it allows the use of MS-based label-free quantitation (i.e. no need for stable isotopes or isotopic 
tags) to compare the relative abundance of a protein across multiple LC-MS/MS experiments. 
The twelve-concentration antibody competition profile as well as the five-concentration tested 
for Gpc2 and Htra1 provided sufficient power to the statistical analysis. The use of a gradual 
increase of free antibody concentrations is providing additional confidence in the obtained 
results compared to more classical binary comparisons. 
Experimental parameters such as the number of antibody concentrations and replicates, are 
adjustable and may need to be fine-tuned for each particular experiment. For example in this 
thesis, decreasing the number of concentrations from twelve to five has been compensated by 
increasing the number of replicates from one to three. 
Reducing even further the number of concentration was tested on the NS5A dataset. An 
analysis using only three concentrations (0, 1.7 and 24 μg/ml) resulted in a different list with 
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twenty-five significant hits (Figure 4.1, pAdj ≤ 0.05, as applied in the original analysis). Among 
the twenty-five, nine proteins (NS5A, NP1L4, PKHG2, FBW1B, NP1L1, PI4KA, UBP19, 
LATS1 and LATS2) overlapped with the twelve concentrations analysis. UBP19 is found with 
four protein quantitation groups, thus three being redundant. A visual inspection of the 
displacement profiles of the thirteen additional proteins clearly flags eleven of them (OST48, 
NCRP1, ELAV1, EFTU, PLAK, RS5, XRN2, FOXK1, CSN2, FOXK2, and DSC1) as false 
positives, if considering the three- as instead of the twelve-concentrations analyses. Two 
proteins are not found at all (bottom row, VAPA and PGAM5) whereas two other proteins 
(ANKY2 and SMYD3) could be considered as potential candidates (p-values of 7% and 40% 
in the twelve-concentrations experiment, respectively). 
In summary, the statistical analysis applied would exceed the limits of its validity by reducing 
the sample size from twelve to three concentrations and the effort to generate additional data 
points is largely compensated by a lower investment to validate fewer hits with higher 
confidence. 
 
Figure 4.1: Statistical power of ICC-MS model. Relative abundance plotted against all 12 
concentrations, with three concentrations (0, 1.7 and 24 μg/ml) plotted in red. 
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The ultimate goal of ICC-MS is to provide a manageably short list of proteins, which have a 
high chance of being successfully validated in orthogonal follow-up experiments. P-values are 
indicative and allow ranking based on confidence of interaction. Nevertheless, it cannot be 
claimed that proteins below a given statistical threshold are absolute binders of a specific 
protein, and directly above the threshold are non-binding. The more rigorous the threshold is, 
the shorter the list, and subsequently the higher the confidence. At the same time, the chance 
of missing some true binders is also increased. 
 
4.4 Further validation of interacting candidates 
ICC-MS is a powerful approach to identify physical interactions in a protein complex. Once 
the list of interacting candidates is generated, some open questions remains: 
1. Is the identified interaction confirmed by another approach? 
2. Is the interaction identified in a test tube also occurring in a compartmentalized living 
cell? 
3. Is the identified interaction ultimately leading to a biological function? 
To address the first question, combination with orthogonal methods is the most efficient 
strategy to improve confidence in identified PPIs. In this thesis, coIP experiments have been 
performed and validated ICC-MS findings (LATS/NS5A, Gpc2/FGF2, Htra1/tubulin, 
Htra1/C1TNF5). Although only a handful of candidates are identified when applying ICC-MS, 
text mining as well as biological expertise will always be taken into account to decide on which 
proteins to follow up. With ICC-MS data only, it is not possible to distinguish direct from 
indirect interactions. SPR is a method of choice to confirm direct binding and to derive affinity 
values as well as kinetics [140] but it requires the production of a purified recombinant protein 
retaining the structural integrity of the endogenous form. 
The second question can be addressed by fluorescence microscopy using genetically expressed 
fluorescent proteins such as fluorescent two-hybrid cellular assay (F2H) [141]. This technique 
relies on co-localization studies of fluorescently-tagged proteins in BHK cells comprising a lac 
operator stably integrated in the nucleus. An attempt have been performed to further confirm 
HtrA1 binding to tubulin and C1QTNF5 in collaboration with Philip Kaiser from NMI (data 
not shown) but the experiment failed probably due to the high aggregation rate of HtrA1. At 
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the end only a minor amount of HtrA1 protein was most likely accessible for binding to 
C1QTNF5 or tubulin respectively. 
Affinity, kinetic and spatial co-localization are giving some indications about the nature of the 
interaction at the cellular level but at the end are not a guarantee of biological functional 
relevance. Assays applied for functional validation are numerous and will greatly depend on 
the type of protein identified (e.g. in vitro phosphorylation for LATS kinases, replication 
capacity of Con1-NS5A-Ser71Ala, impact of LATS silencing on viral replication, proliferative 
effect of increasing concentration of Gpc2). 
It is highly challenging to prove or disprove the functional relevance of an interaction and at 
the end any interactions can be ultimately considered as an evolutionary reservoir for future 
functional interactions. In addition, although many strategies are available to increase the 
confidence towards true interactors, the issue of false negative or missed interactions remain, 
a subset of the interactome only often being probed. 
 
4.5 Applicability to the profiling of ASO-protein interactions 
The combination of competitive capture with MS is a valuable tool to screen not only protein-
protein interactions (ICC-MS) but also RNA-protein interactions (OCC-MS). Nevertheless, the 
specific study of ASO-protein interactions turned out to be more challenging as ASO are by 
nature binding to many proteins/complex of proteins by offering an extended surface with 
multiple points of contact (not like an hydrophobic pocket as for small molecule-protein 
interactions). Many binders are competing or cooperating for a specific site or backbone which 
will be influenced by multiple factors such as the concentration of the protein and of the ASO, 
the presence of recognition motifs, specific chemical modifications, etc. 
OCC-MS alone will not be sufficient to confidently link an interaction with a specific 
intracellular protein to an observed in vivo toxicity profiles. Nevertheless it revealed that a 
greater number of binders is potentially translating in stronger induced in vitro hepatotoxicity 
(see section 3.3.3.). Previously published data using protein microarrays is aligned with such 
hypothesis [142]. Efforts are currently ongoing to further support this observation by profiling 
ASOs with distinct in vivo toxicity profiles directly in tissue extracts (liver and kidney). 
Despite the inherent complexity of ASO-protein interactions, OCC-MS has been capable of 
revealing a cellular “core proteome”, i.e. a few interacting partners consistently identified 
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irrespectively of the cell type or of the sequence of the oligonucleotide. Indeed, comparing 
ASO-B/C/D cellular pull-downs, 34 proteins have been identified as ASO-interacting partners 
across all datasets (Figure 4.2 A) with an handful already published in another RNA centric 
study [119] (Figure 4.2 B, in red). 
 
Figure 4.2: Cellular core binders. Statistical relevant interacting partners consistently identified in 
pull-downs from cellular extracts (identified with at least 2 unique peptides, pAdj < 0.5, signal reduction 
> 50% and with highest abundance when no competition). (A) Venn diagram 
(http://bioinformatics.psb.ugent.be/) comparing ASO-D in Hek293, ASO-B (including R2: replicate 2) 
and ASO-C in PTEC TERT1. (B) The 34 protein candidates were loaded in STRING DB (https://string-
db.org/) using the highest confidence (0.900) in term of interaction score from curated databases (blue 
lines) as well as experimentally determined (pink lines). In bold, known RNA-binding proteins; 
underlined, known DNA-binding proteins; in italic, zinc-finger proteins; in red, proteins also reported 
in [119]. 
The further confirmation of functionally relevant interactions is even more challenging given 
the high number of potential candidates identified. Follow-up experiments to distinguish direct 
versus indirect binders or to verify biological relevance for so many candidates is not feasible. 
OCC-MS statistical model can probably be optimized to deal better with the high number of 
potential binders. Indeed, even at high pAdj values (up to ~50%) some candidates were still 
displaying a reasonable displacement with increasing concentrations of free ASO indicating a 
failure in the power of our test for statistical significance. This can be explained by the fact that 
the model is assuming that the majority of the proteins are not affected by the increase in free 
competitor, which is not true for ASO pull-downs. The model has been designed to reduce as 
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much as possible the identification of false positives but not false negatives. In any cases, 
although a definite nominal value cannot be set, pAdj values can still be used for ranking (from 
the most significant to the least). 
It should be noticed that our approach might be too artificial when dealing with ASO as the 
vast majority of ASOs remains trapped in endocytic compartment and travel via particles [119]. 
Hence many of the identified ASO-binding proteins would even not be encountering the ASO 
in a system where compartmentalization is preserved. Techniques like UV crosslinking 
immunoprecipitation (CLIP) or RNA-protein interaction detection (RaPID) using proximity-
dependent protein labeling in intact live cells can help addressing this limitation [143-145]. 
As observed in section 3.3.3, a minor chemical modification can have a dramatic impact on 
ASO protein binding profile. Modification having no impact on RNA affinity and antisense 
activity while decreasing the number of interacting partners are representing promising strategy 
to design safer ASO. OCC-MS could support the selection of the most appropriate 
modification. 
Therefore OCC-MS could be used as a qualitative way to profile ASOs, ranking them based 
on their protein binding affinity. OCC-MS could guide chemistry to mitigate cellular toxicity 
and ultimately in vivo hepatotoxicity or nephrotoxicity. Overall, OCC-MS could represent an 
additional approach contributing to the improvement of ASO therapeutic index. 
 
4.6 The relevance of ICC-MS and OCC-MS approaches in therapeutic research 
ICC-MS and OCC-MS have been shown to have the potential to contribute to: 
- The identification of novel therapeutic targets, e.g. Further investigations are of course 
required to clearly define the role of LATS kinases but LATS1 and LATS2 could be 
considered as interesting new host targets for the development of future classes of HCV 
therapeutic agents. 
- The discovery of potential novel biomarkers, e.g. FGF2 together with Glypican-2 as 
CSF biomarker for neurogenesis.  
- The relevance of targets for a specific pathology, e.g. Htra1 for AMD. 
- MoA understanding, e.g. SMN splicing modifiers. 
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In addition determination of sites of PPIs by mutagenesis, protein purification, peptide 
mapping/arrays or X-ray crystallography can provide extremely useful information for 
designing specific small molecules. Those approaches are usually challenging as well as time 
consuming, as some proteins are difficult to express or crystallize. 
Developing a new drug is associated with extreme efforts and late stage failure of a drug 
candidate is a dramatic loss primarily for the patients and also in terms of investments. 
Investing efforts in target biology and disease mechanisms understanding during the drug 
development process is part of the strategies developed by pharmaceutical companies to select 
the most efficacious and safest molecules for clinical testing [146]. Indeed a better 
understanding of target biology can not only bring confidence towards its relevance to treat a 
specific pathology but can support early safety de-risking as well as guide the selection of 
appropriate pre-clinical models. In case of failure, a deep understanding of target biology can 
even lead to drug repositioning. 
 
4.7 Outlook 
In this thesis, a novel unbiased platform to screen protein-protein interactions in protein 
extracts with high specificity has been developed. The number of candidates emerging being 
limited, this allows for interaction confirmation via orthogonal methods and further functional 
validation. The effort of combining AP-MS with competitive binding is largely compensated 
by a lower investment to validate fewer hits with higher confidence. 
The workflow is simple but would greatly benefit both in term of time and reproducibility from 
an automation option. A 96 well plate format using AssayMAP Bravo platform from Agilent 
is currently being assessed using streptavidin cartridges to capture biotinylated antibodies. In 
addition to the benefit of automation, the nature of streptavidin/biotin interaction will greatly 
reduce any issue associated with antibody leakage. The samples processing for further MS 
analysis will be also associated with faster protocols based on on-beads digestion altogether 
allowing for an improvement in overall throughput. 
Based on the proof-of-principle studies described in this thesis and the future improvements 
made to the protocol, ICC-MS should remain an attractive approach to better understand targets 
biology and support their relevance as therapeutic targets. 
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6.2 Contributions 
ICC-MS has been designed and optimized at Roche Pharma Research & Early Development, 
Roche Innovation Center Basel in collaboration with Dr. Angélique Augustin and Sabrina 
Golling. 
ICC-MS statistical model has been designed at Roche Pharma Research & Early Development 
Roche Innovation Center Basel in collaboration with Dr. Jens Lamerz. Statistical analysis were 
performed in collaboration with Dr. Jens Lamerz (NS5A, SMN, Gpc2), Dr. Balazs Banfai 
(SMN, OCC-MS), Dr. Gonzalo Duran-Pacheco (SMN, Gpc2) and Dr. Juliane Siebourg-Polster 
(Htra1) at Roche Pharma Research & Early Development Roche Innovation Center Basel. 
- Biological applications of ICC-MS & OCC-MS 
 Characterization of NS5A protein interactome in a cellular model of hepatitis C virus 
replication (Biology leader Dr. Jujun Gao). 
 Characterization of Glypican-2 protein interactome in a human neural stem cell model 
(Biology leader Dr. Sebastian Lugert). 
 Characterization of the HtrA1 protein interactome in a polarized retinal pigmented 
epithelial (RPE) disease model (Biology leader Dr. Esther Melo). 
 Application to decipher survival of motor neuron (SMN) splicing modifiers mode of 
action (Biology leaders Dr. Friedrich Metzger and Dr. Manaswini Sivaramakrishnan). 
 Application to GalNac and naked ASOs with distinct in vitro nephrotoxicity prediction 
(Biology leaders Dr. Sabine Sewing and Dr. Annie Moisan). 
 Application to ASOs with distinct in vitro hepatoxicity profiles (Biology leader Dr. 
Andreas Dieckmann). 
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unbiased approach to study endogenous protein-protein interactions» selbständing verfasst, nur 
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wissenschaftlicher Praxis der Universität Tübingen (Beschluss des Senats vom 25.5.2000) 
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